Artiï¬cial Intelligence in the Life Sciences 1 (2021) 100005 

Contents lists available at ScienceDirect 

Artiï¬cial Intelligence in the Life Sciences 

journal homepage: www.elsevier.com/locate/ailsci 

Signal Detection in Pharmacovigilance: A Review of Informatics-driven 
Approaches for the Discovery of Drug-Drug Interaction Signals in Diï¬€erent 
Data Sources 

Heba Ibrahim a , b , âˆ— , A. Abdo a , Ahmed M. El Kerdawy c , d , A. Sharaf Eldin a , e 
a 
Department of Information Systems, Faculty of Computers and Artiï¬cial Intelligence, Helwan University, Egypt 
b 
Egyptian Pharmaceutical Vigilance Center, Egyptian Drug Authority (EDA), Egypt 
c 
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Egypt 
d 
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, New Giza University, Egypt 
e 
Faculty of Information Technology and Computer Science, Sinai University, Egypt 

a r t i c l e 

i n f o 

a b s t r a c t 

Keywords: 
Machine Learning 
Data Mining 
Adverse Drugâ€“Drug Interaction 
Signal Detection 
Pharmacovigilance 

The objective of this article is to review the application of informatics-driven approaches in the pharmacovigilance 
ï¬eld with focus on drug-drug interaction (DDI) safety signal discovery using various data sources. Signal can be a 
new safety information or new aspect to already known adverse drug reaction which is possibly causally related 
to a medication/medications that warrants further investigation to accept or refute. Signals can be detected 
from diï¬€erent data sources such as spontaneous reporting system, scientiï¬c literature, biomedical databases and 
electronic health records. This review is substantiated based on the fact that DDIs are contributing to a public 
health problem represented in 6-30% adverse drug event occurrences. In this article, we review informatics- 
driven approaches applied by authors focusing on DDI signal detection using diï¬€erent data sources. The aim 
of this article is not to laboriously survey all PV literature. As an alternative, we discussed informatics-driven 
methods used to discover DDI signals and various data sources reinforced with instances of studies from PV 
literature. The adoption of informatics-driven approaches can complement and optimize the practice of safety 
signal detection. However, further researches should be carried out to evaluate the eï¬ƒciency of those approaches 
and to address the limitations of external validation, implementation and adoption in real clinical environments 
and by the regulatory bodies. 

1. Introduction 

1.1. Pharmacovigilance background 

Drug safety monitoring identiï¬ed as Pharmacovigilance (PV) is for- 
mally deï¬ned by the â€œWorld Health Organization (WHO) â€ as â€œthe sci- 
ence and activities relating to the detection, assessment, understand- 
ing and prevention of drug-related problems â€ [1] . PV may be classiï¬ed 
into two categories: (1) preauthorization PV concerning the informa- 
tion adverse drug events accumulated from clinical trial settings (phase 
0/I through phase III) [2] ; and (2) postmarketing/post-authorization PV 
concerning the safety information collected during post-authorization 
life cycle. Even though pre-authorization clinical studies (i.e. RCTs) are 
deliberated as the lineament of explaining a drug eï¬ƒcacy, they donâ€™t 
usually detect whole safety concerns of a certain drug before its use 
in the real world due to well-known limitations. Those limitations can 
be summarized in the restricted sample of trial participants involved in 

âˆ— 

Corresponding author. 
E-mail address: pharma_heba@hotmail.com (H. Ibrahim). 

those studies compared to the total targeted population who may experi- 
ence the drug whenever marketed, the limited interval of drug exposure 
per each study participant especially if the drug projected for chronic 
use, lack of possibly risky patient subpopulations who are usually omit- 
ted from clinical trials (e.g., patients with impaired organs, elderly pa- 
tients, children, and childbearing woman who may be pregnant or lac- 
tating mother, patients on chemotherapy) [3] . Furthermore, RCTs canâ€™t 
detect rare/very rare adverse drug reactions (ADRs) (with occurrences 
of 1/10000 and 1/100000, respectively) or latent ADRs ( > 6 months) 
[4] . That said, the drug eï¬ƒcacy information from premarketing RCTs 
is generally more comprehensive and reliable, whereas complete safety 
proï¬les canâ€™t be established [4] . These boundaries impose obligations of 
both marketing authorization holders and regularity authorities to con- 
tinuously monitor, collect, assess, and draw conclusions and appropriate 
actions to keep positive beneï¬t-risk ratio as long as the drug exists in 
market. 

https://doi.org/10.1016/j.ailsci.2021.100005 
Received 9 March 2021; Received in revised form 26 June 2021; Accepted 27 June 2021 
Available online 8 July 2021 
2667-3185/Â© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 

H. Ibrahim, A. Abdo, A.M. El Kerdawy et al. 

1.2. Drug-drug interaction detection 

One of the leading causes of global morbidities and treatment failure 
is interaction between drug agents. About 30% of unexpected adverse 
drug events may be accounted for Drug-drug interactions (DDIs) [5] . In 
acknowledgment of adverse drug eï¬€ects is a chief reason of product at- 
trition in late stages of the drug development cycle, the earlier detection 
of the interaction proï¬les of novel drug candidates is still intractable. 
In conventional drug development process, many of candidates of novel 
therapeutics are investigated afore triaging a slight quantity of eligi- 
ble molecules, ordinarily depends on prior scientistsâ€™ experience in the 
therapeutic domain and are nominated for subsequent laboratory and 
preclinical testing. Regular drug discovery process includes the delivery 
of new candidates from basic medicinal scientists into testing in pre- 
clinical phases followed by a conduction of diï¬€erent clinical trials. Un- 
predictable drug interactions may result in serious health outcomes and 
consequently undesirable inï¬‚uences on the whole drug discovery pro- 
gression. Accordingly, an increasing demand for developing informatics- 
based frameworks to discover safety comprehension in terms of clini- 
cal practice and originate DDIs of novel therapeutic nominees earlier 
in drug development through multidisciplinary linking between clinical 
and preclinical information. [6] . 

Additionally,  premarketing  clinical  studies  donâ€™t  usually  explore 
DDIs but rather emphasize on investigating the eï¬ƒcacy and safety of 
individual medications [7] . Since patients on polypharmacy are not usu- 
ally included in clinical trials. Furthermore, whenever DDIs are doubted, 
sampling biases and cohort sizes bound the capability for identifying 
rare adverse reactions [8] . Interactions between drugs may take place 
when sharing the same target proteins, pharmacological and metabolic 
pathways leading to aï¬€ecting the safety and/or eï¬ƒcacy proï¬le of phar- 
maceutical products. In other means, the co-administration may consid- 
erably aï¬€ect the eï¬ƒcacy and/or safety proï¬les of a drug agent. Un- 
predictable DDIs are recognized only through signal detection prac- 
tices and postmarketing life cycle [9] . The magnitude of a DDI seri- 
ousness warrants diï¬€erent regulatory actions grading from label infor- 
mation changes into market withdrawals [10â€“12] . Due to the limita- 
tions and diï¬ƒculties in monitoring interaction proï¬les of drugs, mul- 
tiple informatics-based researches have been emerged in recent years 
for DDI discovery via adopting machine learning (ML) and data mining 
methods from heterogeneous data sources. 

DDIs can be classiï¬ed by various criteria. With regard to severity , 
interactions are frequently characterized by three categories according 
to severity into (minor, moderate and major) [13] . Those interactions 
having minimal clinical consequences and minimal risk are classiï¬ed as 
minor DDIs. Moderate DDI is with moderate clinical signiï¬cance, usu- 
ally avoid these combinations and they may be used only under special 
circumstances with closer monitoring and may require dosage changes. 
Major DDI is with high clinical signiï¬cance probably leading to seri- 
ous clinical outcomes should be averted due to negative beneï¬t-risk 
ratios. 

In terms of mechanism , DDIs are classiï¬ed as either pharmacody- 
namic (PD) or pharmacokinetic (PK) [ 14 ]. It is noteworthy that PD â€“
based DDIs make up a smaller class than PK-based DDIs. A Pharmaco- 
dynamic (PD) interaction occurs when the pharmacological eï¬€ect of a 
drug is aï¬€ected by another as a result of: 1) direct eï¬€ect at target site, 
(2) interference with biological or physiological signaling pathways, re- 
sulting in additive, or antagonistic eï¬€ects, or synergistic/ indirect phar- 
macologic eï¬€ect [ 15 ]. Pharmacokinetic (PK) interaction occurs when a 
drug inï¬‚uences the disposition of another drug in the body by interfering 
its absorption, distribution, metabolism, or elimination (ADME) proper- 
ties, causing an altered plasma concentration of the ï¬rst drug that may 
lead to detrimental consequences (treatment failure or toxicity). Within 
the pharmacokinetic processes, the metabolism part covers the largest 
[ 16 ]. A recent study [ 17 ] has estimated that the PK-based DDIs occur at 
metabolic level as follows: (i) 64% of PK-related DDIs involve induction 
or inhibition of the hepatic cytochromes that are accountable for medi- 

Artiï¬cial Intelligence in the Life Sciences 1 (2021) 100005 

cations metabolism, (ii) while 20% of PK DDIs result from transporters 
and 2% from carriers. 

1.3. The concept of Safety Signal Detection 

According to the WHO, safety signal is deï¬ned as â€œreported in- 
formation on a possible causal relationship between an adverse event 
(AE) and a drug, of which the relationship is unknown or incompletely 
documented previously â€ [ 1 ]. The practice of â€œsignal detection â€ is typ- 
ically meant for marketed drugs where a safety concern may be new 
in nature not recognized in premarketing phases or a novel pattern of 
already known adverse drug reaction in terms of (severity, high risk 
sub-population, frequency, etc.). Signal detection can be â€œqualitative â€
built on case-by-case assessment of individual case safety reports) or 
â€œquantitative â€ via adopting machine learning or mining approaches us- 
ing databases of real world data from clinical trials, electronic health 
records, biomedical literature, pharmacological databases, etc. Quan- 
titatively/qualitatively detected signals necessitates further validation 
and conï¬rmation by clinical judgment [ 18 ]. 

The aims of SD practices are to earlier discover potential safety con- 
cerns (completely novel or new pattern to previously known ADR); to 
distinguish signal of higher-order associations; to conï¬rm signals that 
have been ï¬rst identiï¬ed from qualitative avenues; and to probably de- 
tect class eï¬€ect safety issues. 

1.4. Scope 

In this paper, a systematic review was mainly conducted to formulate 
an answer to the question â€œHow were informatics-driven approaches 
in terms of data mining and machine learning applied by researchers 
to identify DDI safety signals? The diï¬€erent aspects informatics-driven 
models existing in the underlying article are shown below in Section 7 - 
Fig. 5 . 

In order to address the main objective of this review, a search strat- 
egy was conducted using the most prestigious biomedical literature 
databases (PubMed, ScienceDirect, Scopus, and Google Scholar). No 
time constraints were applied to be able to retrieve all potential rele- 
vant articles. The following eligibility criteria were used to ï¬nd relevant 
studies: 

Inclusion criteria 

â€¢ Research/regular papers and review articles provided a ML frame- 

work for DDI prediction; 

â€¢ Research/regular papers provided a data mining method for drug 

safety signal detection; 

â€¢ Included information about evaluation for an informatics frame- 

work; 

â€¢ Written in English 

Exclusion criteria 

â€¢ Studies not related to the detection or prediction of DDIs; 
â€¢ Studies not applying any machine learning or data mining tech- 

niques; 

â€¢ Studies not containing any quantitative results; 
â€¢ Studies with only pharmacological scope; 
â€¢ Not written in English. 

As a summary, the remainder of this review is organized into dif- 
ferent sections. We ï¬rst discuss common data sources used in pharma- 
covigilance. We then explore informatics methods based on data mining 
techniques typically used by regulatory bodies for the quantitative PV 
signal detection and categories of ML algorithms deployed in DDI pre- 
diction. Finally, we draw conclusions along with outlining limitations 
and recommendations for future researches. 

2 

H. Ibrahim, A. Abdo, A.M. El Kerdawy et al. 

Artiï¬cial Intelligence in the Life Sciences 1 (2021) 100005 

2. Widespread data sources in support of Pharmacovigilance 

2.1. Postmarketing Pharmacovigilance Data: Spontaneous reporting 
systems 

Postmarketing PV data are mainly available in several unique data 
sources through Spontaneous reporting systems (SRSs). This type of 
spontaneous data is the main source for postmarketing monitoring un- 
til now. SRSs are large databases for collecting individual case safety 
reports (ICSRs) of suspected adverse events passively reported to reg- 
ulatory authorities by patients, healthcare professionals, and industry. 
The VigiBase (the WHO-UMC global database of ICSRs) [ 19 ], US Food 
and Drug Administration (FDA) adverse event reporting system (FAERS) 
[ 20 , 21 ], the European EudraVigilance [ 22 ], and the â€œvaccine adverse 
event reporting systems (VAERS) â€ [ 23 ] are the most prominent ICSRs 
management systems. 

Such kind of SRSs are developed to enable continuous monitoring of 
pharmaceutical and biological products within pharmacovigilance sys- 
tems [ 24 ]. Generally, the structure of SRSs adheres to the international 
safety reporting guidance issued by the International Conference on Har- 
monisation (ICH E2B) that sets standards for reporting individual case 
safety reports (ICSR) [ 25 ]. Other type of SRSs is the proprietary com- 
pany safety databases that contain ICSRs of a company pharmaceutical 
products. They can support early safety signal detection. The merits of 
SRSs are represented in providing information necessary for establishing 
causality assessment from real data and/or developing mining/ML mod- 
els that might not be available in other data sources. For example but 
not limited to, apparent temporal time relationship, concomitant med- 
ications, indications, de-/re-challenge information, some demographic 
patient data, and action taken & outcome Information. Despite multi- 
beneï¬ts of SRSs which playing a crucial role to support wise therapeu- 
tic decision-making in regulatory bodies, they have well-known bound- 
aries. Those limitations can be summarized in over-/under- reporting 
rates, limited past medical history of patients, false signaling due to mis- 
attribution to hidden confounders/risk factors, and inability to indicate 
real incidence rates. 

2.2. Electronic Healthcare Data 

Electronic healthcare data consists of multiple sources like electronic 
health records (EHRs), administrative and insurance claims databases. 
EHRs are a kind of longitudinal observational systems where patientsâ€™ 
medical records are created from multiple systems in healthcare or- 
ganization(s). Many of the EHR ï¬elds are composed of unstructured 
data (e.g. discharge summaries, lab test ï¬ndings, nurse notiï¬cations, 
etc.) and non-speciï¬c adverse events. Natural language processing (NLP) 
studies show how using EHRs data via adopting text mining approaches 
can be beneï¬cial for extracting, encoding, and detecting safety signals 
[26â€“29] . The main beneï¬t of EHRs from the aspect of PV is their capabil- 
ity to conduct active surveillance from real-work data [30â€“32] . Merits 
distinguish EHR systems from SRSs can represented in: not containing 
duplicates, largely unaï¬€ected by under- or over-reporting as they typ- 
ically derived automatically, providing consistent information on most 
of the subjectâ€™s drug exposure periods, clinically relevant events (inde- 
pendently from the exposure status) and valuable information on ex- 
posed subjects without events, and much more complete assessment 
of drug exposure and comorbidity status. For that, EHR systems may 
generate safety signals earlier than SRSs. Nevertheless, the abovemen- 
tioned limitations consider the key boundaries for applying in regular 
PV. Other limitations can be represented in: diï¬ƒculty to access due to 
privacy issues, and very challenging policy and technical issues to inte- 
grate EHRs from multiple sources. In EHRs, elevated rates of a medical 
diagnosis may indicate a safety issue (if subsequent to prescription), so 
some studies have hypothesized that metrics based on exploring longi- 
tudinal observational dataset for temporal associations between events 
over time rather than person-counts could produce more accurate as- 

sociations. Mining of the EHRs data provides patterns of relationships 
among various entities oï¬€ering enhanced medical intelligence unobtain- 
able by other means [33,34] . 

2.3. Biomedical Literature 

In the context of PV, biomedical literature may provide important 
medical data, from preclinical researches, clinical trials, observational 
studies, and case reports, which can be missed in regulatory PV ac- 
tivities due to focusing on coded and structured SRSs data. Addition- 
ally, drug interactions are frequently reported in pharmaceutical jour- 
nals and technical reports, making medical literature the most eï¬€ective 
source for the detection of DDIs. Therefore, developing NLP methods 
aiming at mining drug safety information for either single drug-adverse- 
event combinations or higher-order associations have been grown in re- 
cent years [35â€“37] . Despite its merits, this type of data sources has a 
number of deï¬ciencies that can be summarized as following: (1) Infor- 
mation comprehensiveness is limited due to restricted ï¬nancial access 
to many databases, ignorance of their existence by many people, non- 
standardization of their interface formats, in addition non-user friendly 
search engines; (2) Information quality is limited because no uniform 
guidelines exist for contents of the major text ï¬elds in database records 
(abstracts, titles, keywords, descriptors); (3) Compatibility among the 
contents of all record ï¬elds leading to diï¬€erent perspectives of the same 
technical topic; (4) Information retrieval is limited because time, cost, 
technical expertise, and substantial detailed technical analyses are re- 
quired to retrieve the full scope of related records in a comprehensive 
process; (5) Unï¬ltered nature of biomedical literature is too statistically 
noisy to allow accurate signal detection. These deï¬ciencies can result 
in two serious limitations: a substantial amount of relevant literature 
is not retrieved, and a substantial amount of non-relevant literature is 
retrieved [36] . In summary, it is very challenging to detect drug safety 
signals due to high statistical noise of the biomedical literature, so high 
quality text mining algorithms and/or machine learning needed to be 
developed [37] . 

2.4. Biomedical Knowledge Databases 

There  are  a  number  of  freely  available  biomedical  knowledge 
databases, for example, DrugBank, STITCH, and PharmGKB [38â€“40] , 
support authors to develop representation frameworks targeting the pre- 
diction of safety signals. This kind of resources provides information 
about drugsâ€™ chemical structures, biological elements, targets of phar- 
macological actions, functional/metabolic pathways, etc. Making use of 
this type of data sources oï¬€ers some privileges, for example, allowing 
the opportunity to predict early-stage attrition due to new therapeutic 
candidatesâ€™ toxicities during drug-development process [ 41 ]. This type 
of data sources has limitations represented in: (i) diï¬ƒculty of modeling 
and simulating multifaceted metabolic pathways for thousands of drug 
candidates as it is crucial to preprocess molecules extracted from those 
databases with a set of cleaning rules to be representative dataset; (ii) 
no available databases completely describe the exact mechanisms by 
which drugs and genes may interact; (iii) complex informatics methods 
are required to explore those chemical or genetic data. 

3. Data mining methods for Pharmacovigilance signal detection 

3.1. Disproportionality analyses 

Data mining is the process of extracting the patterns, associations 
or relationships among raw data using diï¬€erent analytical techniques 
involving the creation of a model to derive useful knowledge [42,43] . 
In PV, the data mining techniques are dedicated for hypothesis genera- 
tion of new possible adverse drug events â€. Quantitative signal detection 
practices in large databases (e.g. VigiBase) are founded on data mining 
algorithms using disproportionality analyses (DPAs) [44,45] . DPAs are 

3 

H. Ibrahim, A. Abdo, A.M. El Kerdawy et al. 

Artiï¬cial Intelligence in the Life Sciences 1 (2021) 100005 

Fig. 1. Venn Diagram illustrating the entries {a, b, c, d} of con- 
tingency table. a, number of reports containing both the suspect 
drug and the suspect adverse event; b, number of reports containing 
the suspect drug with other adverse events (except the event of in- 
terest); c, number of reports containing the target adverse event with 
other medications (except the drug of interest); d, number of reports 
containing other medications and other adverse events. 

categorized into two general classes (frequentist and Bayesian). Both 
categories utilize the entries of confusion matrix (as shown Fig. 1 ) to 
compute the magnitude of statistical association between drug-adverse- 
event combinations (DECs)  in a PV database [ 46 ]. Their principles 
depend on estimating observed-to-expected reporting ratios for drug- 
reaction pairs using the total number of cases in background [47â€“52] . 
They quantify the unexpectedness of adverse event being reported to 
a drug or drug pair. All DPAs share the same basic of disproportion- 
ate reporting between observed to expected ratios, despite they diï¬€er 
in computation per each. Whenever a DECâ€™s DPA computation exceeds 
the predeï¬ned minimum thresholds, it will be ï¬‚agged as a statistical 
safety signal that requires further clinical assessment. Diï¬€erent thresh- 
olds are used for these algorithms to identify signiï¬cant safety signals for 
DECs. 

3.2. Association Rule Mining 

Besides DPAs, there is an algorithm called association rule mining 
(abbreviated  as  ARM)  [ 53 ].  ARM  is  considered  a  well-known  min- 
ing algorithm for disclosing interesting patterns concealed within large 
databases. This algorithm was ï¬rst advanced since more than a decade 
to be applied to the ï¬eld of computer science, then expanded to various 
sciences [54â€“56] . Some studies have adopted ARM-based algorithms to 
detect adverse DDI patterns using SRSs [ 57 ]. Apriori algorithm is a kind 
of association rules mining which oï¬€ers an appropriate representation 
of sparse data for complex computations [ 53 ]. Any association rule can 
be expressed in the form of ğ‘¥ â†’ ğ‘¦ where x is an element from X item- 
set, while y is an element from Y itemset, noting that x & y are diï¬€erent 
items. To estimate directionality, the general Apriori algorithm works in 
two steps. The key of primary step is built on counting a frequent item 
set when an observed association between items exceeds the support 
threshold. While the second step depends on generating conï¬dent asso- 
ciation rules fulï¬lling predeï¬ned minimum thresholds. From the scope 
of PV, ğ‘‹ symbolizes an itemset of medications and y symbolizes an item- 
set of adverse-reactions. A signiï¬cant association rule indicates that a 
speciï¬c DEC exceeds minimum thresholds of minimum conï¬dence and 
support. The support of a DEC ğ‘†( ğ‘‹) is the observed numerals of reports 
having ğ‘‹. While support of an association rule ğ‘†( ğ‘‹  â†’ ğ‘Œ ) can be sym- 
bolized as ğ‘†( ğ‘‹  âˆª ğ‘Œ ) . The conï¬dence of an association rule ğ¶( ğ‘‹  â†’ ğ‘Œ ) 
indicates ( ğ‘†( ğ‘‹  âˆª ğ‘Œ ) ) âˆ• ( ğ‘†( ğ‘‹) ) ( 1 ). Conï¬dence deï¬nes how frequently 
objects in Y represented in reports containing X. Conï¬dence enables the 
estimation of conditional likelihood ( ğ‘ƒ ğ‘Ÿ ( ğ‘Œ )âˆ•( ğ‘‹) ) ( 2 ) of Y in presence of 
X. An interesting association is ï¬‚agged when a rule fulï¬lls the minimum 
thresholds of both support & conï¬dence, however some studies have 
suggested other measures to ï¬lter signiï¬cant DDI associations [ 53 ]. 

3.3. Regression-based Approaches 

Confounders are hidden covariates that may be hidden factors lead- 
ing to either ï¬‚agging spurious safety signals or delaying the detection 
of signiï¬cant ones [ 58 ]. It is worth mentioning that confounders may 
infer a risk factor predisposing the adverse reaction or a key to identify 
higher risky patient subpopulations. A simpler type of confounders can 
be seen in variables (for example, age, gender, and year). They may be 
handled eï¬€ectively by the stratiï¬cation for each stratum using Mantelâ€“
Haenszel adjustments [59,60] . Nevertheless, adjusting huge numerals of 
possible confounders may result in missing signal detection in a timely 
manner [61â€“63] . Another limitation is represented in stratiï¬cation by 
gender, age-group, etc. where the number of case reports are low and 
then infeasible to conduct subgroup analyses. Additionally, there are 
other forms of confounders called â€œinnocent bystander â€ responsible for 
the occurrence of adverse events such as interacting drugs or indica- 
tions of reported comedications. Unfortunately, using Mantelâ€“Haenszel 
approaches for adjusting such kind of confounders is ineï¬€ective [ 60 ]. 
For large numbers of covariates, adopting logistic-regression (LR) ap- 
proach is more eï¬ƒcient [ 61 ]. 

LR extends linear regression function by a sigmoid function to a value 
interval from 0 to 1 [ 62 ]. LR computes ROR by categorizing databaseâ€™s 
records as case-control records where a case is counted whenever hav- 
ing adverse-event of interest, whereas controls are counted whenever 
records having other adverse-events. In the context of PV, two studies 
have reported adopting LR modeling using SRSs aiming at DDI signal de- 
tection [63,64] . The comprehension of LR can be expressed according 
to the following formula: 
)
(
ğ‘¥ 
1 , ğ‘¥ 
Ì‚ğ‘¦ = Ì‚ğ‘ 
2 

1 + Ì‚ğ›½ğ‘› ğ‘¥ ğ‘› 

0 + Ì‚ğ›½

= log 

=  Ì‚ğ›½

1 ğ‘¥ 

(3) 

ğ‘ 
1 âˆ’ ğ‘ 

Where  Ì‚ğ‘¦  denotes  predicted  outcome;  Ì‚ğ›½
0 = Slope; ğ›½n = coeï¬ƒcient of covariates n, X 
x 
tors or features covariates. 

0  =  coeï¬ƒcient  of  slope; 
n = number of predic- 

4. Paradigms of data mining and text mining studies using 
spontaneous reporting systems for detecting DDI signals 

Nevertheless the limitations of any â€œspontaneous reporting system 
(SRS) â€ in regular PV practices, SRSs provide precious tool in detecting 
previously unknown safety concerns [ 65 ]. DPAs represent the most com- 
monly applied algorithms in the area of quantitative signal detection 
within health authorities and large pharmaceutical industry [66,67] . 

The Shrinkage measure Î©, which is the extension of IC measure for 
the triplets {drug-drug-AE}, has been innovated by NorÃ©n et al . at Up- 
psala monitoring Centre (UMC) to screen potential DDI signals in the 

4 

H. Ibrahim, A. Abdo, A.M. El Kerdawy et al. 

Artiï¬cial Intelligence in the Life Sciences 1 (2021) 100005 

VigiBase [ 9 ]. Authors have shown the privileges of Î© shrinkage mea- 
sure compared to logistic regression in detecting interesting patterns of 
DDI signals. It can be calculated by estimating the proportion between 
observed and expected frequencies as seen in the following equation; 

Î© =  ğ‘™ğ‘œ ğ‘” 
2 

ğ‘› 111 + ğ›¼
ğ¸111 + ğ›¼

(4) 

Where E111 stands for the â€œexpected â€ incidence value of drug-drug- 
event combination within a PV database; a is a constant equals to 0.5; 
Î©025 is the lower boundary of 95% conï¬dence interval which ï¬‚ag a 
statistical DDI signal when its value â‰¥ 0 [ 9 ]. In 2013, Choi et al. have 
investigated the feasibility of using the national Korean health insurance 
system named â€œHIRA â€ in identifying DDI signals [ 68 ]. They adopted 
the shrinkage measure Omega Î© on the ICD-10 codes of diagnoses in 
association with a standard DDI dataset of NSAID and diuretics. 

A Reporting ratios (RR) was used, as a conditional disproportionality 
analysis, to assess the increased of users searching for hyperglycemia- 
related terms given that they searched for both pravastatin and parox- 
etine. The results provided evidence to the potentiality of prediction of 
drug safety signals from search logs. 

Almenoï¬€ et al . have examined the Bayesian disproportionality mea- 
sure MGPS (90% conï¬dence interval) in screening interaction proï¬les 
between antihypertensive drug â€œverapamil â€ and other classes of car- 
diovascular medications [ 69 ]. Results have shown the usefulness of 
MGPS disproportionality algorithm in mining DDI interesting patterns 
in polypharmacy conditions. Schuemie et al. [ 70 ] proposed an approach 
known as longitudinal GPS (LGPS) which is a modiï¬cation of the orig- 
inal MGPS approach. LGPS computed the expected number of medi- 
cal events during drug prescriptions based on an aggregate unexposed 
patient-time in exposed and unexposed patients. For protecting against 
confounding from dominating unexposed patients so long as the major- 
ity of the patients in a population donâ€™t receive speciï¬c medicine, au- 
thors suggested a ï¬lter named Observational Proï¬les of Adverse events 
Related to Drugs (LEOPARD) to eliminate spurious associations caused 
by protopathic bias. LGPS has been shown to outperform related meth- 
ods, including MGPS. 

In 2010, Harpaz et al. [ 71 ] have proposed an enhanced Apriori al- 
gorithm using FAERS data for the purpose of detecting interesting DDI 
patterns. Because of the unsuitability of classic Apriori metrics for drug 
safety ï¬eld, RRR measure was utilized instead, with supplementary ï¬l- 
ter that each drug pair in association triplet should have RRR score 
higher than any of each drug individually. The second ï¬lter criterion 
was aimed to eliminate spurious DDI signals. Results exhibited nearly 
35% of the drug-drug-reaction associations relating to well-known DDI, 
thus indicating the probable beneï¬t of custom ARM in ï¬‚agging poten- 
tial DDI signals that warrant further clinical assessment. Another study, 
Ibrahim, H et al . [ 72 ] have presented an augmented data mining al- 
gorithm â€œhybrid Apriori â€, customized to PV applications, where dis- 
proportionality PRR measure was adopted as interestingness measure 
to discover association patterns of adverse DDIs from FAERS data. On 
the other side, Van Puijenbroek et al. [ 73 ] have considered an adjusted 
disproportionality measure ROR through implementing a model of lo- 
gistic regression on the Netherlandsâ€™s PV database â€œLAREB â€ to evalu- 
ate the adverse eï¬€ects for the coadministration of â€œnon-steroidal anti- 
inï¬‚ammatory drugs (NSAID) â€ and â€œdiuretics â€ on worsening the symp- 
toms of congestive heart failure (CHF) disease. Results implied that us- 
ing NSAIDs themselves has no role in increasing the risk of CHF. While 
upon coadministration with diuretics, NSAIDs have contributory role in 
aggravating CHF. The authors have concluded that adopting LR can of- 
fer advantages over bivariate disproportionality measures via guarding 
against false signals as a result of confounding by concomitant medica- 
tions. 

Thakrar et al . have illustrated the principal of multiplicative and ad- 
ditive modeling in discovering DDI signals using SRS [ 74 ]. The design 
of multiplicative/additive framework was built on estimating the inter- 
action coeï¬ƒcient ( ğ›¿) where the associated risk with drug pair coadmin- 

istration is larger than those observed with each drug individually. In- 
creased risk of a particular safety concern linked to speciï¬c drug(s) can 
be represented in higher incidence rates, higher observed-to-expected 
ratios, observed disproportionate reporting, etc. The statistical formula 
for a multiplicative model of â€œinteraction coeï¬ƒcient ğ›¿â€³ associated with 
a drug pair can be calculated by a logarithmic linear regression equation 
as follows: 

ğ¿ğ‘œğ‘” ( ğ‘Ÿğ‘–ğ‘ ğ‘˜ ğ‘œğ‘“ ğ‘’ğ‘£ğ‘’ğ‘›ğ‘¡ ) = ğ›¼ + ğ›½ ( ğ‘‘ğ‘Ÿğ‘¢ğ‘” ğ´ ) + ğ›¾ ( ğ‘‘ğ‘Ÿğ‘¢ğ‘” ğµ ) + ğ›¿ ( ğ‘‘ğ‘Ÿğ‘¢ğ‘” ğ´ ğ‘ğ‘›ğ‘‘ ğµ ) 

+ ğ‘œğ‘¡â„ğ‘’ğ‘Ÿ ğ‘ğ‘œğ‘£ğ‘ğ‘Ÿğ‘–ğ‘ğ‘¡ğ‘’ğ‘  

(5) 

While the statistical formula of the additive model for an â€œinteraction 
coeï¬ƒcient ğ›¿â€³ associated with a drug pair can be calculated as shown in 
the below equation. 

ğ‘…ğ‘–ğ‘ ğ‘˜ ğ‘œğ‘“ ğ‘’ğ‘£ğ‘’ğ‘›ğ‘¡ = ğ›¼ + ğ›½ ( ğ‘‘ğ‘Ÿğ‘¢ğ‘” ğ´ ) + ğ›¾ ( ğ‘‘ğ‘Ÿğ‘¢ğ‘” ğµ ) + ğ›¿ ( ğ‘‘ğ‘Ÿğ‘¢ğ‘” ğ´ ğ‘ğ‘›ğ‘‘ ğµ ) 

+ ğ‘œğ‘¡â„ğ‘’ğ‘Ÿ ğ‘ğ‘œğ‘£ğ‘ğ‘Ÿğ‘–ğ‘ğ‘¡ğ‘’ğ‘  

(6) 

The principal of multiplicative model is based on assuming that a 
safety concern accompanied with a medication is multiplied to its back- 
ground estimate, whereas the principal of additive model is founded 
on adding the safety concern linked to a drug into its background esti- 
mate. Regarding the multiplicative model, supposing the null hypothesis 
is real (i.e., non-DDI), the proportional risk of drug-drug-adverse-event 
combination is equal the product of the proportions of each drug individ- 
ually ( ğ‘ƒ ğ‘…ğ‘…ğ´ğµ = ğ‘ƒ ğ‘…ğ‘…ğ´ Ã— ğ‘ƒ ğ‘…ğ‘…ğµ) ( 7 ). Likewise the additive model, if 
the proportional risk of an adverse event (AE) associated with a particu- 
lar drug-pair is equal to the sum of proportions for the same AE of inter- 
est associated with each drug individually ( ğ‘…ğ‘…ğ´ğµ = ğ‘ƒ ğ‘…ğ‘…ğ´ + ğ‘ƒ ğ‘…ğ‘…ğµ) 
( 8 ). DDI signal generated when multiplicative model ğ‘ƒ ğ‘…ğ‘…ğ´ğµâˆ• ğ‘ƒ ğ‘…ğ‘…ğ´ Ã—
ğ‘ƒ ğ‘…ğ‘…ğµ  >  1 or additive model ğ‘ƒ ğ‘…ğ‘…ğ´ğµ  âˆ’ ğ‘ƒ ğ‘…ğ‘…ğ´ âˆ’ ğ‘ƒ ğ‘…ğ‘…ğµ  >  0 along 
with signiï¬cant p - ğ‘£ğ‘ğ‘™ğ‘¢ğ‘’  <  0 . 05 . The additive model in the context of 
DDI signal detection has shown higher sensitivity results compared to 
the multiplicative one. Hence, multiplicative models can be complemen- 
tary evidence for DDI signals detected by the additive models. 

There are diï¬€erent types of unstructured data sources which can be 
represented in narrative portions of EHRs, biomedical databases, etc. 
In recent years, researchers have proposed methods for mining such 
sources to eï¬€ectively predict adverse DDI signals making up for the lim- 
itations of spontaneous reporting systems. Algorithms related to text 
mining and natural language processing (NLP) are commonly utilized 
to evolve these tasks. 

Iyer et al . [ 75 ] have proposed an approach of natural language pro- 
cessing for disclosing DDI signals directly from the embedded verbatim 
parts of two big corpora of EHRs. They adopted adjusted disproportion- 
ality measures to detect signiï¬cant associations of DDIs composed of 
1165 distinct drugs and 14 distinct AEs. The authorsâ€™ method has shown 
comparable performance between the DDIs signals discriminated from 
EHRs and those identiï¬ed from SRSs. 

Jon D. Duke et al . [ 76 ] have developed a new approach to mine 
mechanistic features from PV literature abstracts to predict potential 
DDI signals. Authors have speciï¬cally investigated interesting DDI pat- 
terns associated with the increased risk of myopathy and related mus- 
culoskeletal conditions. First, the authors applied two-step Information 
Retrieval (IR) approach to recognize the expression patterns relevant 
to DDI from PubMed abstracts. Then, they performed two logistic re- 
gression analyses to test each DDI eï¬€ect on myopathy. They validated 
clinically signiï¬cant DDI signals via using a database of electronic health 
records. Five novel DDI signals of increased risk of myopathy along with 
related cytochrome metabolizing enzymes were predicted. 

LePendu et al . [ 77 ] proposed an approach for mining textual clini- 
cal notes corresponding to 1,044,979 patients derived from the Stanford 
Translational Research Integrated Database Environment (STRIDE) us- 
ing odds ratio (OR) as frequency-based association measure. In purpose 
of generating hypotheses of DDIs signals, authors have used unstruc- 
tured notes of EHRs rather than SRSs. Authors have evaluated their sug- 
gested approach in terms of sensitivity and speciï¬city using gold stan- 

5 

H. Ibrahim, A. Abdo, A.M. El Kerdawy et al. 

Artiï¬cial Intelligence in the Life Sciences 1 (2021) 100005 

dard of known interactions from DrugBank and the MediSpanÂ® Drug 
Therapy Monitoring System TM (Wolters Kluwer Health, Indianapolis, 
IN). In overall, authorsâ€™ method achieved 81.5% area under the Receiver 
Operator Characteristic (ROC) curve for signaling known DDIs. 

Segura et al . [ 78 ] proposed the shallow linguistic kernel technique 
for automatic DDIs extraction from biomedical texts. As the recogni- 
tion of drug names is an essential prerequisite step for the automatic 
discovery of DDIs from biomedical texts, authors used UMLS MetaMap 
Transfer (MMTx) tool to automatically identify drug entities occurring 
in unstructured textual documents of DDIs from DrugBank database. 
The MMTx recognizes and annotates drug entities according to UMLS 
semantic types (e.g., Clinical Drug [clnd], Pharmacological Substance 
[phsu], and Antibiotic [antb]). Drug-DDI corpus was created, annotated 
with 3169 DDIs, as the output of MMTx in XML format. Also, MMTx 
tool was used to extract and label candidates of drug pairs with 1 if in- 
teraction exists or labeled 0 if no interaction exists. The performance 
of proposed shallow linguistic kernel-based technique, with a precision 
of 51.03%, a recall of 72.82% and an F-measure of 60.01%, conï¬rmed 
the remarkable impact of automatic entity recognition on the relation 
extraction task. 

In 2013, White et al . [ 79 ] have demonstrated that the internet search 
logs that are generated by consumers are able to provide early clues 
about DIAEs. The authors conducted a large scale study of web search 
log paying attention on speciï¬c interaction between paroxetine (an an- 
tidepressant) and pravastatin (a cholesterol-lowering drug), which was 
recently reported in 2011 to cause hyperglycemia. Yang et al . [ 80 ] pro- 
posed a text mining methodology where they used social media to iden- 
tify DDI patterns by combining ARM and lexicon-based algorithms. The 
authors used a data source called â€œMedHelp â€ as an example for an on- 
line healthcare forums. Only triplets were considered whereas each co- 
occurrence was counted for a pair of interacting drugs associated with 
an adverse event. They examined the signiï¬cance of the constructed 
drug-drug-adverse-event associations using 4 metrics as follows {sup- 
port, leverage, lift, and conï¬dence} [ 81 ]. Some limitations related to 
the previous mentioned measures for example, the leverage could be 
very small or even negative because of the very small of threads related 
to ADR compared with the total number of threads. For that, authors 
adopted another measure called interaction ratio to capture DDI signals 
through which variation of conï¬dence can be calculated. The generated 
patterns have proven the feasibility of the proposed approach in DDI 
signal detection from DrugBank database. 

5. Machine learning approaches for the prediction of safety 
signals 

In recent years, research eï¬€orts have directed from data mining ap- 
proaches towards machine-learning (ML) to discover DDIs early during 
the drug discovery process before becoming commercially available. ML 
methods can be characterized into two broad categories: supervised and 
unsupervised [ 82 ]. In supervised learning, a model is built prior to the 
analysis where the model learns from labeled input data in order to esti- 
mate speciï¬c relationships between the features and the labels of the in- 
put data. Then, the learned model is applied to unseen data to predict the 
category or quantity of interest. Classiï¬cation and regression are very 
common supervised learning techniques used in biomedical research. It 
is worth mentioning that regression-based approaches are traditionally 
adopted for either biostatistics or data mining purposes as illustrated in 
section 4 . However, in several studies either linear or logistic regression 
are considered as ML models for binary/multi-class prediction of con- 
tinuous/categorical features. Supervised ML algorithms may be used for 
feature selection, classiï¬cation, prediction or evaluating the eï¬ƒciency 
of some parameters [ 83 ]. In contrast, for unsupervised learning, the al- 
gorithm is applied directly on unlabeled input data to ï¬nd regularities, 
and then a model will be built according to the identiï¬ed patterns. Clus- 
tering and biclustering algorithms are the most common unsupervised 
ML techniques [ 84 ]. The following subsections from 5.1 through 5.5 

6 

summarize the most common ML algorithms adopted by researchers in 
the ï¬eld of safety signal detection. 

5.1. Support Vector Machine 

Support vector machine (SVM) is the most popular non-probabilistic 
ML algorithm which was ï¬rst developed by Vapnik and Lerner for bi- 
nary classiï¬cation problems [ 85 ]. The main concept of SVM is to create 
the optimal hyperplane/decision boundary. A hyperplane is a line/(n- 
1) dimensional plane that can separate n-dimensional input space into 
two classes so that a new data point can be easily categorized into the 
correct class [ 84 , 86 ]. There are two types of SVM: linear SVM and non- 
linear SVM depending on whether data are linearly separable or not. For 
linear SVM, the distance between the decision boundary and the closest 
data points is referred to as the margin. As shown in Fig. 2 , the optimal 
hyperplane is the line with the largest margin that can separate the two 
classes. The margin is calculated as the perpendicular distance from the 
hyperplane to only the closest points referred to as the support vectors 
of the hyperplane. Only these points are relevant in deï¬ning the line 
and in the construction of the classiï¬er. 

The real-world applications of SVM is subject to non-linearly sepa- 
rable data where a linear decision boundary cannot be used to classify 
the dataset. This leads to the emerging of a new generation of learn- 
ing systems called kernel functions. A SVM Kernel is a function where it 
takes input training dataset with non-linearly separable decision surface 
and transforms the low-dimensional feature space into an abstract high- 
dimensional space. The most common kernel functions used in SMV 
modeling are Gaussian radial basis function (RBF), polynomial, and sig- 
moid kernels [ 87 ]. 

In this, we can conclude the merits and demerits of SVM. The key 
advantage is the kernel trick that enables SVM to create non-linear max- 
imum margin decision boundaries in the original non-linearly separable 
feature space and consequently allows SVM to operate well in high- 
dimensional spaces. While disadvantages are represented mainly in: (i) 
Long training time for large datasets; (ii) its black-box nature that makes 
the ï¬nal model diï¬ƒcult to interpret. 

5.2. K-Nearest Neighbors (KNN) 

K-nearest neighbors (KNN) is a popular ML algorithm belonging to 
the family of instance-based learning for the purposes of classiï¬cation 
and regression prediction [88,89] . KNN at its core is a distance-based 
algorithm where the distance between two objects/data rows is calcu- 
lated. KNN typically requires the calculation of distances between an 
example and k samples in the training dataset with the smallest dis- 
tance to determine the prediction. While in the test set, the class label is 
predicted by only calculating distances for the nearest k neighbors (see 
Fig. 3 ). The most commonly used distance metrics in this regard are 
â€œEuclidean distance â€ and â€œHamming distance â€ [90,91] . â€œEuclidean dis- 
tance â€ metric is computed as the square root of the sum of the squared 
diï¬€erences between the two vectors as seen in the following formula: 

ğ· ğ¸ ğ‘¢ğ‘ğ‘™ğ‘–ğ‘‘ ğ‘’ğ‘ğ‘› ( ğ‘, ğ‘ ) = 

âˆš âˆš âˆš âˆš 

ğ‘˜ âˆ‘

(

)
2 
ğ‘ ğ‘– âˆ’ ğ‘ ğ‘– 

ğ‘– =1 

(9) 

While the â€œHamming distance â€ metric computes the distance be- 
tween two binary vectors to the sum of the bit diï¬€erences between bi- 
nary strings as seen in the following formula: 

ğ· ğ»ğ‘ğ‘šğ‘šğ‘–ğ‘›ğ‘” ( ğ‘, ğ‘ ) = 

ğ‘˜ âˆ‘

|
|
|ğ‘ ğ‘– âˆ’ ğ‘ ğ‘– 
|

ğ‘– =1 

(10) 

Here ğ‘ = ( ğ‘ 

1 ,  â€¦ .,  ğ‘ ğ‘˜ ) and ğ‘ = ( ğ‘ 

1 ,  â€¦ .,  ğ‘ ğ‘˜ ) refer to vectors in k- 
dimensional space. The notations â€œğ‘ & ğ‘â€ are two objects in n-space; 
â€œğ‘ ğ‘–  & ğ‘ ğ‘– â€ are vectors starting from the origin of the space (initial 
point/object); n denotes n-space. 

H. Ibrahim, A. Abdo, A.M. El Kerdawy et al. 

Artiï¬cial Intelligence in the Life Sciences 1 (2021) 100005 

Fig. 2. Schematic representation of linear support vector ma- 
chine algorithm concept . The ğœ” denotes the normalized vector to the 
decision hyperplane; Horizontal and vertical axes (X 
2 ) symbol- 
ize the feature space (feature 1 & feature 2). 

1 and X 

Fig. 3. Schematic representation of k-Nearest Neighbor (KNN) algo- 
rithm concept. Where, k = number of neighbors; X 
2 are the input 
descriptors; Red star is the query instance [89] . 

1 & X 

The main advantage of KNN algorithm is its capability to arbitrar- 
ily approximate any data distribution. However its demerits can be 
abridged as follows: (i) Computationally challenging as KNN uses all 
data points of the loaded training dataset for conducting queries; (ii) the 
number of data needed to be scaled grows exponentially with dimension 
by increasing the dataset size. It is known as the â€œcurse of dimensional- 
ity â€. 

5.3. Random Forest Classiï¬er 

Ensemble learning is a general meta-approach that combines predic- 
tions from multiple ML models to achieve better predictive performance. 
One of the powerful ML algorithm based on bagging ensemble learning 
is random forest classiï¬er (abbreviated as â€œRFC â€). It was developed by 
Leo Breiman [ 92 ]. Bagging is one of the main standard strategies used in 
ensemble learning techniques that ï¬ts many decision trees on diï¬€erent 
samples of the same dataset and averages the predictions (see Fig. 4 ) 
[ 93 ]. 

RFC is a supervised learning algorithm that is based on the infras- 
tructure of decision tree algorithm and to classify either categorical or 
continuous features [ 94 ]. It estimates numbers of decision tree classi- 
ï¬ers which ï¬t on various subsets of a training dataset to augment the 
predictive performance and manage overï¬tting compared to â€œDecision 
tree algorithm â€ (refer to Fig. 5 ). The considered number of features at 
each sub-tree equals to the square root of the number of features in the 
input training dataset. Then, it averages the scores of each decision tree 
to predict the class of the test dataset instance [95,96] . 

Besides the high variance associated with tree classiï¬ers due to sub- 
stantial change in the training dataset resulting in very diï¬€erent sub- 
trees and being non-interpretable, RFC is still privileged as a relatively 
fast training model that requires little data preparation can be adopted 
for multidimensional problems [97,98] . 

5.4. Artiï¬cial Neural Networks 

Artiï¬cial Neural Networks (ANN) are a set of algorithms developed 
to imitate the neurons in human brain that are designed to recognize 
patterns in data which may be used for classiï¬cation or clustering prob- 
lems [99,100] . There are two main categories of ANN: (i) simple neural 
networks; (ii) deep learning neural networks (refer to Fig. 6 ). We here 
outline the general ANN architectures and common activation functions 
with taking into consideration deep learning neural networks are out of 
scope of the underlying review where ANNs. 

There are two speciï¬c architectures for ANNs: (1) Feed-forward neu- 
ral networks and (2) Feedback/Recurrent neural networks. Feed-forward 
neural networks are the most common architecture of ANN in practical 
applications. In this architecture, the information travels in one direc- 
tion towards the output layer with one or multiple hidden layers. While 
Feedback/recurrent neural networks (RNNs) are more ï¬‚exible and much 
diï¬ƒcult to analyze than feed-forward networks. RNNs can process vari- 
able length inputs by processing them in time steps, allowing the output 
of deeper layers to be fed back to previous layers in subsequent time 
steps. Therefore this type of ANN is typically utilized in sequential and 
time-series tasks. 

Fig. 7 shows scheme of an interfacial neuron where a sequence of 
three operations can be represented as follows: (1) take an input feature 
ğ‘– for a vector ğ‘‹ and assign it a weight, then sum those inputs to obtain 
modulated features coming to the body of the neuron, and ï¬nally have 
an activation function ğ‘“ â€œPerceptron â€ that transforms those modulated 
features into the ultimate output/class [ 96 ]. 

There are various types of activation functions but the most com- 
mon ones used in ANN modeling are Heaviside step function [ 101 ], Sig- 
moid function [ 102 ], Hyperbolic Tangent function (Tanh) [ 103 ], Recti- 
ï¬ed Linear Unit (ReLU) [ 104 ], Softmax function [ 105 ]. Heaviside step 
function is the classic and simplest ANN activation function with bi- 

7 

H. Ibrahim, A. Abdo, A.M. El Kerdawy et al. 

Artiï¬cial Intelligence in the Life Sciences 1 (2021) 100005 

Fig. 4. Schematic representation of bag- 
ging ensemble learning concept. 

Fig. 5. Comparison of (a) decision boundaries of decision tree classiï¬er versus (b) decision boundaries of random forest classiï¬er on classic example â€œIris dataset â€. 

nary outcome that was ï¬rst developed by Frank Rosenblatt (Refer to 
the â€œblue circle â€ in Fig. 7 above). It outputs 0 if the score is â‰¤ 0, and 1 
otherwise. 

Sigmoid is a non-linear activation function which is also known as 
â€œLogistic function â€. It provides a smooth and diï¬€erentiated gradient 
curve. Sigmoid is typically used as the activation function in binary 
classiï¬cation problems where its prediction output is normalized into 
the range [0â€“1]. Like Sigmoid, Hyperbolic tangent activation function 
is used in binary classiï¬cation problems. Nonetheless, it is zero centric 

and the output values range from -1 to 1. B is the most popular acti- 
vation function used in multiclass classiï¬cation problems besides deep 
learning neural networks applications. ReLU allows the elimination of 
negative units in an ANN which diminish the sparse activation of only 
about 50%. Unlike the previously mentioned activation functions, Soft- 
maxâ€™s output is computed by the probabilities of modulated inputs to 
predict target class with the highest probability. The sum of the entire 
probabilities must be equal to 1. This function is commonly utilized in 
multiclass classiï¬cation problems. 

8 

H. Ibrahim, A. Abdo, A.M. El Kerdawy et al. 

Artiï¬cial Intelligence in the Life Sciences 1 (2021) 100005 

Fig. 6. Main types of artiï¬cial neural networks (ANN). 

Fig. 7. Schematic representation of â€œPerceptron learning rule â€ to im- 
itate an artiï¬cial neuron to biological neuron. ğ‘‹ ğ‘– : Input feature i to 
a vector ğ‘‹ in a single neuron; ğ‘Š ğ‘– : assigned weight for each input 
feature i . 

5.5. Naive Bayes 

Naive Bayes (NB) is one of the simplest supervised ML algorithms 
that is suitable for binary and multiclass classiï¬cation of categorical in- 
put features. NB is based on Bayesâ€™ theorem to estimate posterior proba- 
bility with the assumption of independence between features [ 106 ]. The 
comprehension of NB as a probabilistic classiï¬er can be expressed as in 
the following equation: 

ğ‘ƒ ( ğ‘ |ğ‘¥ ) = 

ğ‘ƒ ( ğ‘¥ |ğ‘ ) ğ‘ƒ ( ğ‘ ) 
ğ‘ƒ ( ğ‘¥ ) 

(9) 

Where ğ‘ƒ ( ğ‘ğ‘¥ ) denotes the posterior/conditional probability of class 
(target) given predictor (feature); ğ‘ƒ ( ğ‘) is the prior probability of class; 
ğ‘ƒ ( ğ‘¥ğ‘ ) symbolizes the likelihood which is the probability of predictor 
given class and ğ‘ƒ ( ğ‘¥ ) represents the prior probability of predictor. 

The merit of NB modeling is that it is easy to build with no compli- 
cated iterative parameter estimation. It is particularly useful to imple- 
ment on large datasets [ 107 ]. However, the main limitation of NB is the 
assumption that all the predictor features are completely independent. 

6. Paradigms of machine learning studies for prediction of DDI 
signals 

In the light of principles of the state-of-art ML algorithms described 
throughout section 5 , in this section, we present paradigms of ML studies 
reported in biomedical literature. Two main types of ML approaches - 
(network-based [108â€“111] and similarity-based [ 17 , 112â€“120 ]) - have 
been adopted by researchers for the purposes of predicting DDI safety 
signals. 

Regarding network-based ML methods , they have been proposed by re- 
searchers for diï¬€erent objectives, including DDI prediction, drug-target- 
interaction (DTI) prediction, adverse drug reaction prediction, or drug 
repurposing [ 121 ] . For discovering unknown DDI signals, the strate- 

gies of network-based ML approaches depend on inferring drug simi- 
larities between network nodes or learning about topological features 
of the network structure [122,123] . Those knowledge networks can be 
constructed by extracting and integrating existing drug knowledge from 
one or multiple data sources (e.g. chemical, biological, target, genomic, 
pharmacological databases) leading to various shapes of networks (e.g. 
drug-drug, drug-target, protein-protein, pharmacodynamic, drug-gene, 
phenotypic, pharmacokinetic, etc.) [ 124 ]. 

Cami et al., [ 108 ] suggested a predictive pharmacointeraction net- 
works (PPIN) framework to predict DDIs by utilizing the network topo- 
logical structure for all known DDIs of a knowledge database â€œMul- 
tum Vantage Rx â€, a commercial available database of curated DDIs 
and related side eï¬€ects. Based on intrinsic and taxonomic properties 
of drugs nodes and edges representing interaction between nodes, the 
PPIN has reported 48% sensitivity, 90% speciï¬city and 81% area un- 
der the receiver operating characteristic curve (AUROC). On the other 
hand, Huang et al. , [ 109 ] have conducted a study based on protein- 
protein-interaction (PPI) network for systematic prediction of PD DDIs. 
They designed two metrics of network topology to integrate pheno- 
typic & genomic similarities between drug pairs. Numerous PD DDIs 
have been discovered with high accuracy score (0.82) and modest re- 
call score (0.62). In 2014 [ 111 ], Cheng et al., adopted a heterogeneous 
network-assisted inference (HNAI) framework for large-scale prediction 
of ligandâ€“receptor DDIs. Their work depended on integrating drug phe- 
notypic, therapeutic, chemical, and genomic properties. They tested 
ï¬ve ML algorithms: Naive Bayes, Decision Tree, 3-nearest neighbors 
(or 3NN), logistic regression and support vector machine to predict 
DDIs. The key ï¬nding of the HNAI model was a reasonable area un- 
der the receiver operating characteristic (ROC) curve (AUC) (0.67) as 
evaluated using ï¬ve-fold cross-validation. In 2019, Cheng et al. [ 110 ] 
have reported a network-based method for predicting beneï¬cial drug- 
combinations discriminated from adverse DDIs for FDA-approved an- 

9 

H. Ibrahim, A. Abdo, A.M. El Kerdawy et al. 

Artiï¬cial Intelligence in the Life Sciences 1 (2021) 100005 

tihypertensive drugs. Three types of experimentally evidenced clinical 
data sources (FDA-approved drug labels, Database of Clinicaltrials.gov, 
and published preclinical studies) were utilized. In this study two topo- 
logical measures were adopted for capturing associations between ele- 
ments of disease and drugâ€“target networks in the human proteinâ€“protein 
interactome. Network-based proximity measure was used to capture the 
topological linking between two drugâ€“target modules, whereas, Z-score 
was used to get closeness among disease and drug networks. As a re- 
sult, six diï¬€erent relationships of drug-drug-disease modules could be 
distinguished by combining a number of decision rules. 

In recent years, Similarity-based ML frameworks have been greatly 
adopted for classiï¬cation tasks in the ï¬eld of pharmacovigilance, par- 
ticularly DDI prediction compared to feature vector-based frameworks. 
Similarity-based  methods  postulate  that  similar  treatments  may  ad- 
versely interact with the same drug. A Similarity-based ML framework 
ideally composes of ï¬ve phases that can be summarized as follows: 
(i) Feature capturing from one or more data sources; (ii) Constructing 
feature matrices usually show relationships between a drug and fea- 
ture descriptors expressing various relationships between interacting 
drugs from various perspectives. These feature descriptors may reï¬‚ect 
the chemical properties of a drug (e.g. 2d chemical substructures, 3d 
pharmacophores, anatomical therapeutic chemical â€œATC â€ codes, etc.). 
They may also represent pharmacodynamic/pharmacokinetic proper- 
ties of a drug (e.g. target proteins, metabolizing enzymes, transporter 
proteins, and carrier proteins). Moreover, descriptors may reveal some 
pharmacogenomics/ clinical properties (e.g. gene proï¬le, interaction- 
proï¬le, adverse-drug-event (ADE) proï¬le, etc.); (iii) Computing feature 
similarity scores between bit-vectors using various types of similarity 
indices [125â€“134] ; (iv) Implementing the prediction phase by adopting 
well-established ML algorithms; (v) Evaluating predictive performance 
results of the Similarity-based ML framework. 

Those similarity-based ML frameworks have a number of notable 
merits compared to network-based or feature vector-based frameworks: 
(1) They do not require feature engineering that is usually a complex 
procedure; (2) Existing similarity indices (e.g. Tanimoto coeï¬ƒcient) are 
well-developed and broadly used; (3) higher predictive performance 
outcomes. 

Ferdousi et al., [ 17 ] have conducted a recent study for computational 
prediction of DDIs based on the similarities of the biological elements 
between drug pairs extracted from two publically available databases 
(DrugBank & KEGG). They compared 12 similarity measures for their 
ability to recall positive DDIs (i.e. known DDIs). Then, they selected the 
most reliable binary-similarity measure. They could extract 250,000 po- 
tential DDIs categorized as (low, moderate, high, very high) according 
to their prediction scores. They qualitatively validate few of the pre- 
dicted DDI associations and no quantitative performance evaluation has 
been made. Vilar, S. et al., [112â€“115] have conducted a series of stud- 
ies built on similarity-based modeling using DrugBank as a data source. 
The use of drug structural similarity information for DDI prediction gave 
an overall precision of 0.26, sensitivity of 0.68, and speciï¬city of 0.96 
[ 112 ]. Vilar, S. et al. , [ 113 ] have successfully applied a similarity-based 
model for DDI prediction based on the interaction proï¬le ï¬ngerprints 
(IPFs). A database of 17,230 DDI candidates along with their potential 
pharmacological eï¬€ects has been provided for supporting decision in 
DDI detection and pharmacovigilance (PV) data analysis. This method 
has reported precision values ranging from 0.4â€“0.5. Whereas in 2014 
[ 114 ], Vilar, S. et al. , have presented a protocol integrating ï¬ve sim- 
ilarity ï¬ngerprints of drug pairs in purpose of large-scale DDI predic- 
tion. The study reported a robust AUROC > 0.95. Vilar, S. et al., [ 115 ] 
have extended their work in 2015 targeting speciï¬c type of adverse 
DDIs using FDA PV database (FAERS). Their similarity-based method 
depended on capturing chemical and pharmacological features. Their 
results showed enhanced sensitivity, speciï¬city and precision in com- 
parison to the data mining algorithm proportional reporting ratio â€œPRR â€
traditionally applied on PV databases. Likewise, Sornalakshmi et al. , 
[ 116 ] included diï¬€erent similarity measures represented in 2D chem- 

ical structure, 3D pharmacological, interaction proï¬le ï¬ngerprint (IPF), 
target, and ADE from DrugBank and SIDER data sources as ground truth 
for DDI labels, then trained SVM models to predict potential DDIs. Got- 
tlieb, A. et al., [ 117 ] have proposed the inferring drug interactions (INDI) 
method which infers both metabolizing enzyme CYP450-associated PK 
DDIs and PD DDIs based on chemical and side eï¬€ect similarities. They 
made use of two publicly available resources to extract known DDIs & 
their severity. The results showed high AUC value â‰¥ 0.93, in addition to 
high sensitivity and speciï¬city levels by using 10-fold cross-validation. 
Herrero-Zazo et al. [ 118 ] used Lexicomp and Vidal compendia as gold 
standards for DDI labels. They adopted supervised learning models using 
ANN constructed from DrugBank data based on PK and PD properties, 
along with drugâ€“enzymes relationships. Tatonetti et al . have conducted 
a study where data from two diï¬€erent sources (FAERS and HERâ€™s Stan- 
ford hospital) have been linked aiming at detecting DDIs spontaneous 
reporting systems [ 119 ]. A predictive logistic regression model using 
FAERS data source has been constructed where eight classes of seri- 
ous clinical adverse events (SAEs) proï¬les were generated. Two datasets 
were utilized, one for training and the other for testing. Nearly 171 po- 
tential DDI signals have been identiï¬ed which validated using Stanford 
health records. The AUC values ranged from 0.51 to 0.71 for the eight 
models. In Vilar S et al. study, 2018, NLP has been adopted to extract 
the embedded representations of DDIs from PV literature, then apply 
ML to directly make predictions yielding good predictive performance 
in terms of sensitivity, but modest precision with numerous false signals 
[ 120 ]. 

7. Discussion 

This paper investigates pharmacovigilance signal detection for drug- 
drug interactions from several aspects. Based on the illustration pre- 
sented above in sections and subsections, herein we concluded a gen- 
eral framework of informatics-driven modelling that may be used by 
researchers for the purposes of adverse DDIs discovery (as shown in 
Fig. 8 ). One of the main objective of knowledge-based studies is to eval- 
uate the eï¬ƒciency of a model features in discovering novel DDI sig- 
nals. Various metrics were used in purpose of evaluating the capability 
of informatics-based approaches in DDIs prediction. The most common 
metrics utilized in these studies are precision, sensitivity, speciï¬city, 
accuracy, F1-measure and AUROC. Sensitivity indicates how well the 
model distinguishes adverse DDI signals. Speciï¬city measures how well 
the model can disclose non-DDI signals. Accuracy measures how well the 
model can predict both DDI signals and non-DDI signals. AUROC metric 
is mainly used in ML studies to estimate how well speciï¬c descriptors 
can distinguish between two classes (DDI/ non-DDI). 

Table 1 displays a comparison of performance metrics for either data 
mining or machine learning studies â€“ (previously presented in sections 
4.0 & 6.0) â€“ in the context of DDI signal detection. There are no state- 
of-art methods that can be benchmarked. This is due to diï¬€erent subsets 
size, quality & diverse of data preparation approaches, diï¬€erent valida- 
tion methods, etc. Henceforth, in Table 1 , we focused the comparison 
on two main items (research context and data source), besides the well- 
established algorithms per each context (please refer to Fig. 8 ). From 
the data mining perspective, hybrid Apriori seems to provide the best 
performance among data mining algorithms in terms of sensitivity and 
precision. 

Classic PV signal detection practices are focused on adopting DPA 
algorithms to mine SRS data for constituting hypotheses of single drug- 
AE combinations that need further investigation to establish evidenceâ€“
based medicine to conï¬rm or refute causality associations between those 
pairs. Then, regulatory actions may be taken to protect the public health. 
However, there is still limitations towards adopting data mining ap- 
proaches in regular PV practices to generate novel hypotheses for DDI 
signals. Moreover, modest eï¬€orts are in place to mine DDI signals for 
experimental drugs where there is no or limited data in various data 
sources. Wherever a novel hypothesis for DDI signal is created, more 

10 

H. Ibrahim, A. Abdo, A.M. El Kerdawy et al. 

Artiï¬cial Intelligence in the Life Sciences 1 (2021) 100005 

Fig. 8. A multi-layered informatics-driven framework for discov- 
ering drug-drug interactions safety signals. SRS: Spontaneous Re- 
porting System; EHR: Electronic Health Records; PRR: Proportional 
Reporting Ratio; ROR: Relative Odds Ratio; RRR: Relative Report- 
ing Ratio; IC: Information Component; MGPS: Multi-Gamma Poison 
Shrinker; SVM: Support Vector Machine; KNN:  K-nearest neighbor; 
RFC: Random Forest Classiï¬er; LR: Logistic regression; ANN: Artiï¬- 
cial Neural Network; NB: NaÃ¯ve Bayes;  ğ‘¿ 2 
: Chi-Square; NPV: Neg- 
ative Predictive Value; PPV: Positive Predictive Value; AUROC: Area 
under the ROC Curve. 

Table 1 
Summary of the Performance Metrics of Machine Learning and Data Mining methods adopted in the studies described 
in sections 4 and 6 , respectively. AUCROC: Area under the Receiver Operator Characteristic curve; DDI: drug-drug interaction; 
SRS: spontaneous reporting system; ARM: Association rule mining; SVM: Support vector machine; IPF: Interaction proï¬le 
ï¬ngerprint; PPIN: Protein-protein interaction network. 

Method (Measurements) 

Research Objective 

Best Sensitivity 

Best Precision 

Best Speciï¬city 

Best Accuracy 

Best AUROC 

Data mining methods for DDI Signal detection implemented to SRS data 

Association pattern 
recognition (ARM) 

Hybrid Apriori (0.81) 
[72] 

Hybrid Apriori (0.85) 
[72] 

Machine learning methods for DDI Signal detection implemented into biomedical knowledge databases 

Classiï¬cation 
Similarity-based 
modeling 

Network analysis 

Molecular Structure 
Fingerprint (0.96) 
[112] 
PPIN (0.96) 
[106] 

PPIN (0.81) 
[109] 

SVM (0.93) [117] 
IPF (0.96) 
[113] 

11 

H. Ibrahim, A. Abdo, A.M. El Kerdawy et al. 

Artiï¬cial Intelligence in the Life Sciences 1 (2021) 100005 

experimental/clinical investigations may be needed to provide further 
evidences for conï¬rming a DDI signal. Several factors have impact on 
detecting DDI signals where important ones may be missed or spuri- 
ous associations are more likely to be produced. These inï¬‚uences can 
be summarized in: minimal demographic data, duplicated reports, no 
information regarding patient exposure, underreporting that may arti- 
ï¬cially increase expected risk estimates of the drugs, verbatim medical 
terms, unstandardized drug names, etc. Accordingly, optimizing current 
data mining techniques with chosen thresholds aiming at overcoming 
raw data challenges and capturing DDI signals with higher sensitivity 
and precision is crucial. Also, researchers have shown ARM and its ex- 
tended algorithms as good choices for handling the sparse of postmar- 
keting PV data within SRSs where strong association patterns could be 
generated to easily recognize higher order of Drug-AE associations. On 
the other side, adopting EHRs as a complementary source for routine 
PV practices generally and DDI signal detection speciï¬cally is challeng- 
ing. This may be attributed to the ontology problems, heterogeneity of 
data from various sources and patientsâ€™ information are mainly being 
in textual formats, besides confounding by co-medications, risk factors 
and/or comorbidities. Hence, developing NLP approaches and to be in- 
tegrated with regression methods can be an option to handle ontology 
problems along with managing confounders. Another avenue of NLP can 
be adopted in regular PV data in purposes of reducing the large space 
of drug-drug-event associations inherently present in SRSs and allowing 
further processing in the context of DDI signal detection [ 134 ]. 

Whereas from ML perspective, PPIN framework provides a better 
overall performance concerning both accuracy and speciï¬city compared 
to other methods. While, SVM appears to have the best overall DDI pre- 
dictive performance in terms of AUROC compared to other supervised 
ML in predicting DDI signals [135â€“140] . However, SVM has inherited 
limitations represented in the time lapse of model running and the black 
box nature limiting the interpretation of the prediction outcomes. In re- 
cent years, the dawn of adopting supervised ML in PV signal detection 
has resulted from the evolution of multiple useful biomedical knowl- 
edge resources as gold standards of labeled DDIs (e.g. DrugBank [ 141 ], 
KEGG, Micromedex), besides using these resources to assess the predic- 
tive performance of supervised ML avenues. 

The use of supervised ML has its limits such as class imbalance, sparse 
features, low overlapping and consistency between diï¬€erent DDIs re- 
sources [ 142 ]. Therefore, advancements in incorporating unsupervised 
ML approaches in DDIs discovery studies, improvements of DDI cor- 
pora annotation, and establishing standardized guidelines for establish- 
ing DDI gold reference datasets are probably essential steps to develop 
more realistic ML frameworks during drug-development, as well as, pre- 
marketing phases. Other directions of developments to be implemented 
into routine PV practices are represented in how ML may contribute 
in boosting DDI signal detection from SRS data and/or predicting their 
types/change in severity, combining more than one data sources (e.g. 
EHRs, patient support programs, prospective surveys, randomized con- 
trolled trials, etc.) rather than restricting to SRS data, assessing ML al- 
gorithmic performance by constructing reliable test sets, in addition to 
advancing frameworks for increasing transparency or explainability of 
ML outputs. 

According to the abovementioned illustrations and beyond the struc- 
tured PV data sources, the exponential increase of the scientiï¬c liter- 
ature complicates the exploration of such biomedical corpora [ 143 ]. 
Biomedical corpora enables constructing learning datasets of medically 
related terms that embed prior knowledge and aid in the pragmatic use 
of certain words within speciï¬c contexts [ 120 ]. Informatics-based meth- 
ods, in particular text mining and ML frameworks have great applicabil- 
ity in this regard to aid in extracting, analyzing and classifying biological 
information designated in scientiï¬c publications. During the past years, 
biomedical corpora have presented a valuable PV data source for the 
detection and analysis of DDI signals. The unstructured nature of this 
type of data sources is challenging. Natural Language Processing (NLP) 
approaches are crucial in this context to annotate, standardize and map 

relevant medical terminologies and generic drug names is crucial for 
implementing reliable computational models. 

8. Concluding remarks 

The availability of freely available safety data sources along with 
the adoption of novel DM and/or ML methods has advanced the PV 
domain. In this review, we particularly focus on developments in in- 
formatics techniques in the context of DDI signals. We have shown a 
portfolio of PV resources, DM and ML approaches techniques proposed 
to discover adverse DDI signals. Each method may re-stimulate interest 
to evolve DDI surveillance practices by oï¬€ering diï¬€erent prospects. To 
the best we know, the underlying paper is the ï¬rst review combining 
machine learning and data mining methods to disclose potential signals 
of DDIs in drug safety surveillance. Possible causal DDIs associations are 
experimented during drug development cycle, then monitored via post- 
marketing PV systems after being in market. Developing better predic- 
tive methods, to ï¬‚ag potential DDI signals, becomes of great importance 
to industry and regulatory bodies [144,145] . 

The black box nature of ML methods is one of their major limita- 
tions leading to diï¬ƒculty in interpreting of what features are impor- 
tant and/or interpreting the model results. However, generally, adopting 
informatics-driven methods to be implemented in regular drug develop- 
ment process will be valuable. Since this will enable greater linkage 
between basic experimental platforms and controlled clinical settings 
early during drug development phases, then empowering the analysis of 
important safety concerns for investigational drugs at earlier stages lead- 
ing to more eï¬ƒcient triage for novel drug candidates for further steps in 
the development process [ 146 ]. Boosted predictive approaches can be 
achieved by integrating structural and biological knowledge with en- 
riched safety datasets [ 147 ] . Previous studies have shown beneï¬ts from 
linking drugsâ€™ phenotypic, therapeutic, structural, and genomic informa- 
tion in revealing DDI patterns in both drug discovery and postmarketing 
PV processes [148â€“150] . 

Innovative  paradigms  have  arisen  from  exploiting  various  data 
sources compared to conventional PV practices, permitting for the ac- 
tive monitoring of DDI drug proï¬les. As spontaneous systems are con- 
sidered the biggest assembly of real world data for distinguishing DDIs 
[151â€“154] . The discovery of higher-order drugâ€“event combinations is 
more challenging than identifying signals of single drugâ€“event pairs due 
to the limitation of under-reporting rates in large SRSs. Although the 
DDI detection research shifted away from SRSs utilization into other 
data sources in the recent years, this couldnâ€™t replace the main role of 
SRSs in regular PV. Accordingly, more eï¬€orts are required in purposes 
of evolving methods for routine DDIs discovery across diï¬€erent safety 
data sources. 

Also, the main challenge in DDI signal detection studies is the lack 
of well-established guidances for assessing informatics-driven methods 
performance. Principally, this is due to the lack of reference standard for 
interaction safety proï¬les of the whole marketed drug products [ 155 ]. 
Hence, researchers should conduct more studies with purposes for ac- 
quiring better comprehension to the landscapes of multivariate associ- 
ation measures along with estimating corresponding predictive perfor- 
mance. Furthermore, developing approaches targeting the estimation of 
optimal DDI signal detection thresholds that achieve balanced trade-oï¬€
between sensitivity and speciï¬city with decreasing false signals can be 
a valuable perspective. 

In conclusion, informatics-driven approaches donâ€™t prove causality 
association, but instead they can be valuable complementary tool to 
ï¬‚ag hypotheses of DDI combinations and support signal assessment. 
Comprehensive clinical judgment will always endure fundamental for 
establishing causal relationships between drugs and safety concerns. 

Declaration of Competing Interest 

The authors declare that they have no known competing ï¬nancial 
interests or personal relationships that could have appeared to inï¬‚uence 
the work reported in this review paper. 

12 

H. Ibrahim, A. Abdo, A.M. El Kerdawy et al. 

Artiï¬cial Intelligence in the Life Sciences 1 (2021) 100005 

References 

[1] Edwards IR , Aronson JK . Adverse drug reactions: deï¬nitions, diagnosis, and man- 

agement. Lancet 2000;356:1255â€“9 . 

[2] Hartford CG , Petchel KS , Mickail H , Perez-Gutthann S , McHale M , Grana JM , Mar- 
quez P . Pharmacovigilance during the pre-approval phases: an evolving pharma- 
ceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP 
riskmanagement guidelines. Drug Saf 2006;29(8):657â€“73 . 

[3] Sanson-Fisher RW , Bonevski B , Green LW , Dâ€™Este C . Limitations of the randomized 
controlled trial in evaluating population-based health interventions. Am J Prev Med 
2007;33(2):155â€“61 . 

[4] Amery WK . Why there is a need for pharmacovigilance. Pharmacoepidemiol Drug 

Saf 1999;8(1):61â€“4 . 

[5] Pirmohamed D , Orrne ML , et al. Drug Interactions of Clinical Importance. In: 
Davies D, et al., editors. Daviesâ€™s Textbook of adverse Drug Reactions. London: 
Chapman & Hall Medical; 1998. p. 888â€“912. London . 

[6] Gomba VK , Enslein K , Blake BW . Assessment of developmental toxicity potential 
of chemicals by quantitative structureâ€“toxicity relationship models. Chemosphere 
1995;31(1):2499â€“510 . 

[7] Van der Heijden PG , van Puijenbroek EP , van Buuren S , van der Hofstede JW . On 
the assessment of adverse drug reactions from spontaneous reporting systems: the 
inï¬‚uence of underreporting on odds ratios. Stat Med 2002;21(14):2027e44 . 
[8] Olvey EL , Clauschee S , Malone DC . Comparison of critical drug-drug interaction 
listings: the Department of Veterans Aï¬€airs medical system and standard reference 
compendia. Clin Pharmacol Ther 2010;87(1):48e51 . 

[9] NorÃ©n G , Sundberg R , Bate A . A statistical methodology for drug-drug interaction 

surveillance. Stat Med 2008;27:3057â€“70 . 

[10] Bui  PH ,  Quesada  A ,  Handforth  A ,  Hankinson  O .  The  Mibefradil  Derivative 
NNC55-0396, a Speciï¬c T-Type Calcium Channel Antagonist, Exhibits Less CYP3A4 
Inhibition than Mibefradil Drug Metab. Dispos 2008;36(7):1291â€“9 . 

[11] Meinertz T . Mibefradil - a drug which may enhance the propensity for the devel- 

opment of abnormal QT prolongation. Eur Heart J 2001;3:K89â€“92 Suppl . 

[12] US Food and Drug Administration [online]. Available from URL: http://www. 
fda.gov/Drugs/GuidanceComplianceRegulatory . Acessed 20 December 2020. 
[13] Robertson S , Penzak S , Arthur JA , Darrell RA , Charles ED , et al. . Drug Interactions. 
Principles of Clinical Pharmacology. Burlington: Academic Press; 2007. p. 229â€“47 . 
[14] Patsalos PN , Perucca E . Clinically important drug interactions in epilepsy: gen- 
eral features and interactions between antiepileptic drugs. The Lancet Neurology 
2003;2:347â€“56 . 

[15] Opie LH . Adverse cardiovascular drug interactions. Current Problems in Cardiology 

2000;25:628â€“32 . 

[16] Boobis A , Gundert-Remy U , Kremers P , Macheras P , Pelkonen O . In silico prediction 
of ADME and pharmacokinetics: Report of an expert meeting organized by COST 
B15. Eur J Pharm Sci 2002;17:183â€“93 . 

[17] Ferdousi R , Safdari R , Omidi Y . Computational prediction of drug-drug interac- 
tions based on drugs functional similarities. Journal of Biomedical Informatics 
2017;70:54â€“64 . 

[18] Alvarez Y , Hidalgo A , Maignen F , Slattery J . Validation of statistical signal detection 
procedures in EudraVigilance postauthorisation data: a retrospective evaluation of 
the potential for earlier signalling. Drug Saf 2010;33:475â€“87 . 

[19] Lindquist M . VigiBase, the WHO global ICSR database system: basic facts. Drug Inf 

J 2008;42(5):409â€“19 . 

[20] The  (FAERS):  Quarterly  Data  Files.  Available:  http://www.fda.gov/Drugs/ 

GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEï¬€ects/ucm082193.htm . 
Acessed 04 November 2020. 

[21] Zhan C , Roughead E , Liu L , Pratt N , Li J . Detecting high-quality signals of ad- 
verse drug-drug interactions from spontaneous reporting data. J Biomed Inform 
2020;112:103603 . 

[22] EudraVigilance [online]. Available: http://www.ema.europa.eu/ema/index.jsp? 
curl = pages/regulation/document_listing/document_listing_000239.jsp .  Acessed 
11 December 2020. 

[23] Vaccine  adverse  event  reporting  systems  (VAERS).  Available  from  URL: 

https://vaers.hhs.gov/data.html . Acessed 16 December 2020. 

[24] Ivanov S , Lagunin A , Filimonov D , Poroikov V . Assessment of the cardiovascular ad- 
verse eï¬€ects of drug-drug interactions through a combined analysis of spontaneous 
reports and predicted drug-target interactions. PLoS Comput Biol 2019;15(7) . 
on 

E2B 
http://www.ich.org/products/guidelines/eï¬ƒcacy/article/eï¬ƒcacyguidelines.html . 
Acessed 24 October 2020. 

[25] International 

Harmonisation, 

Conference 

ICH 

[26] Wysowski DK , Swartz L . Adverse drug event surveillance and drug withdrawals 
in the United States, 1969-2002: the importance of reporting suspected reactions. 
Arch. Intern. Med. 2005;165(12):1363â€“9 . 

[27] Aronson AR . Eï¬€ective mapping of biomedical text to the UMLS metathesaurus: The 

MetaMap program. In: Proc AMIA Symp.; 2001. p. 17â€“21 . 

[28] Friedman C , Shagina L , Lussier Y , Hripcsak G . Automated encoding of clini- 
cal documents based on natural language processing. J Am Med Inform Assoc 
2004;11(5):392â€“402 . 

[29] Rindï¬‚esch TC , Fiszman M . The interaction of domain knowledge and linguistic 
structure in natural language processing: Interpreting hypernymic propositions in 
biomedical text. J Biomed Inform 2003;36(6):462â€“77 . 

[30] Wang X , Hripcsak G , Markatou M , Friedman C . Drug safety surveillance using de-i- 
dentiï¬ed EMR and claims data: issues and challenges. J Am Med Inform Assoc 
2009;16(3):328â€“37 . 

[31] Segura-Bedmar I , MartÃ­nez P , De Pablo-SÃ¡nchez C . Combining syntactic informa- 
tion and domain-speciï¬c lexical patterns to extract drugâ€“drug interactions from 

13 

biomedical texts. In: Proceedings of the ACM fourth international workshop on 
data and text mining in biomedical informatics (DTMBIOâ€™10); 2010. p. 49â€“56 . 
[32] Gurulingappa H , Mateen-Rajput A , Toldo L . Extraction of potential adverse drug 

events from medical case reports. J Biomed Semantics 2012;20(1):15 3 . 

[33] Dandala B , Joopudi V , Tsou CH , Liang JJ , Suryanarayanan P . Extraction of Infor- 
mation Related to Drug Safety Surveillance From Electronic Health Record Notes: 
Joint Modeling of Entities and Relations Using Knowledge-Aware Neural Attentive 
Models. JMIR Med Inform 2020;10(7):e18417 8 . 

[34] BouzillÃ© G,  Morival  C,  Westerlynck  R,  et  al.  An  Automated  Detection  Sys- 
tem  of  Drug-Drug  Interactions  from  Electronic  Patient  Records  Using  Big 
Data Analytics. Studies in Health Technology and Informatics 2019;264:45â€“9. 
doi: 10.3233/shti190180 . 

[35] Tari L , Anwar S , Liang S , Cai J , Baral C . Discovering drugâ€“drug interactions: a tex- 
t-mining and reasoning approach based on properties of drug metabolism. Bioin- 
formatics 2010;26(18):i547â€“53 . 

[36] Kostoï¬€ R . The extraction of useful information from the biomedical literature. ACA- 

DEMIC MEDICINE 2001;76(12):1265â€“70 . 

[37] Zhang T, Leng J, Liu Y. Deep learning for drug-drug interaction extraction from 
the literature: a review. Brief Bioinform 2020;25(5):1609â€“27 21PMID: 31686105. 
doi: 10.1093/bib/bbz087 . 

[38] DrugBank website. Available at URL: http://www.drugbank.ca/ . Acessed 14 Au- 

gust 2020. 

[39] PharmGKB database. Available from URL: https://www.pharmgkb.org/index.jsp . 

Acessed 09 July 2020. 

[40] Kuhn M , von Mering C , Campillos M , Jensen LJ , Bork P . STITCH: interaction 
networks of chemicals and proteins. Nucleic Acids Res 2008;36(Database is- 
sue):D684â€“8 . 

[41] Vanderwall DE , et al. Molecular clinical safety intelligence: a system for bridging 
clinically focused safety knowledge to earlystage drug discovery - the GSK experi- 
ence. Drug Discov Today 2011;16(15-16):646â€“53 . 

[42] Yang CC, Yang H. Mining heterogeneous networks with topological features con- 
structed from patient-contributed content for pharmacovigilance. Artif Intell Med 
2018;90:42â€“52. doi: 10.1016/j.artmed.2018.07.002 . 

[43] Ting SL , Shum CC , Kwok SK , Tsang AHC , Lee WB . Data Mining in Biomedicine: 
Current Applications and Further Directions for Research. J Software Engineering 
& Applications 2009;2:150â€“9 . 

[44] Noguchi Y , Aoyama K , Kubo S , Tachi T , Teramachi H . Improved Detection Crite- 
ria for Detecting Drug-Drug Interaction Signals Using the Proportional Reporting 
Ratio. Pharmaceuticals 2021;14(4) . 

[45] Noguchi  Y,  Tachi  T,  Teramachi  H.  Comparison  of  Signal  Detection  Al- 
gorithms  Based  on  Frequency  Statistical  Model  for  Drug-Drug  Interac- 
tion  Using  Spontaneous  Reporting  Systems.  Pharm  Res  2020;30(5):86  37. 
doi: 10.1007/s11095-020-02801-3 . 

[46] Hauben M , Zhou X . Quantitative Methods in Pharmacovigilance: focus on signal 

detection. Drug Saf 2003;26(3):159â€“86 . 

[47] Evans SJ , Waller PC , Davis S . Use of proportional reporting ratios (PRRs) for signal 
generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol 
Drug Saf 2001;10(6):483â€“6 . 

[48] Evans  SJ .  Pharmacovigilance:  a  science  or  ï¬elding  emergencies?  Stat  Med 

2000;19(23):3199â€“209 . 

[49] Chee BW , Berlin R , Schatz B . Description: Predicting Adverse Drug Events from 

Personal Health Messages. AMIA Annu Symp Proc 2011:217â€“26 . 

[50] Bate A , Lindquist M , Edwards IR , Olsson S , Orre R , Lansner A , De-Freitas RM . A 
Bayesian neural network method for adverse drug reaction signal generation. Eur 
J Clin Pharmacol 1998;54(4):315â€“21 . 

[51] Bate A , Lindquist M , Edwards IR , Orre R . A data mining approach for signal detec- 

tion and analysis. Drug Saf 2002;25(6):393â€“7 . 

[52] DuMouchel W . Bayesian data mining in large frequency tables, with an application 

the FDA Spontaneous Reporting System. Am. Stat. 1999;53(3):177â€“90 . 

[53] Agrawal R , Imielinski T , Swami A . Mining association rules between sets of items 
in large databases. In: Proceedings of the ACM SIGMOD international conference 
on management of data; 1993. p. 207â€“16 . 

[54] Iskander J , Pool V , Zhou W , English-Bullard R . Data mining in the US using the 

vaccine adverse event reporting system. Drug Saf 2006;29(5):375â€“84 . 

[55] Carrino JA , Ohno-Machado L . Development of radiology prediction models using 

feature analysis. Acad Radiol 2005;12(4):415â€“21 . 

[56] Sarawagi S , Thomas S , Agrawal R . Integrating association rule mining with re- 
lational database systems: alternatives and implications. Data Mining Knowledge 
Discov 2000;4(2):89â€“125 . 

[57] Iyer SV , Lependu P , Harpaz R , Bauer-Mehren A , Shah NH . Learning Signals of 
Adverse Drug-Drug Interactions from the Unstructured Text of Electronic Health 
Records. AMIA Jt Summits Transl Sci Proc 2013:216 . 

[58] Mantel N , Haenszel W . Statistical aspects of the analysis of data from retrospective 

studies of disease. J Nat Cancer Inst 1959;22(4):719â€“48 . 

[59] Noren GN , Bate A , Orre R , Edwards IR . Extending the methods used to screen the 
WHO drug safety database towards analysis of complex associations and improved 
accuracy for rare events. Stat Med 2006;25(21):3740â€“57 . 

[60] Hopstadius J , NorÃ©n GN , Bate A , Edwards IR . Impact of stratiï¬cation on adverse 

drug reaction surveillance. Drug Saf 2008;31(11):1035â€“48 . 

[61] Nicholas P . Jewell.Statistics for Epidemiology. Texts for statistical sciences. Chap- 

man and Hall; 2004. Hardcover edition . 

[62] Van Puijenbroek EP , Egberts AC , Heerdink ER , Leufkens HG . Detecting drug-drug 
interactions using a database for spontaneous adverse drug reactions: an example 
with diuretics and non-steroidal anti-inï¬‚ammatory drugs. Eur J Clin Pharmacol 
2000;56(9-10):733â€“8 . 

H. Ibrahim, A. Abdo, A.M. El Kerdawy et al. 

Artiï¬cial Intelligence in the Life Sciences 1 (2021) 100005 

[63] Van Puijenbroek EP , Egberts AC , Meyboom RH , Leufkens HG . Signalling possible 
drugâ€“drug interactions in a spontaneous reporting system: delay of withdrawal 
bleeding during concomitant use of oral contraceptives and itraconazole. Br J Clin 
Pharmacol 1999;47(6):689â€“93 . 

[64] Van Puijenbroek EP , Egberts AC , Heerdink ER , Leufkens HG . Detecting drugâ€“drug 
interactions using a database for spontaneous adverse drug reactions: an example 
with diuretics and non-steroidal anti-inï¬‚ammatory drugs. Eur J Clin Pharmacol 
2000;56(9-10):733â€“8 . 

[65] Rawlins MD . Spontaneous reporting of adverse drug reactions. II: Uses. Br J Clin 

Pharmacol 1988;26(1):7â€“11 . 

[66] Roux E , Thiessard F , Fourrier A , BÃ©gaud B . Tubert-Bitter P. Evaluation of statistical 
association measures for the automatic signal generation in pharmacovigilance. 
IEEE Tran INF Technol Biomed 2005;9(4):518â€“27 . 

[67] Van Puijenbroek EP , Bate A , Leufkens HG , Lindquist M , Orre R , Egberts AC . 
A comparison of measures of disproportionality for signal detection in sponta- 
neous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 
2002;11(1):3â€“10 . 

[68] Choi CA , Chang MJ , Choi HD , Chung WY , Shin WG . Application of a drug-inter- 
action detection method to the Korean National Health Insurance claims database. 
Regul Toxicol Pharmacol; 2013;67(2):294â€“8 . 

[69] Yang X , Fram D . Using disproportionality analysis as a tool to explore drug-drug 
interavtions in AERS database. Pharmacoepidemiol Drug Safety 2004;13:S247 . 
[70] Schuemie  MJ .  Methods  for  drug  safety  signal  detection  in  longitudinal  ob- 
servational  databases:  LGPS  and  LEOPARD.  Pharmacoepidemiol  Drug  Saf 
2011;20:292â€“9 . 

[71] Harpaz R , Haerian K , Chase HS , Friedman C . Statistical Mining of Potential Drug 
Interaction Adverse Eï¬€ects in FDAâ€™s Spontaneous Reporting System. Proc of AMIA 
Annu Symp 2010:281â€“5128 . 

[72] Ibrahim H , Saad A , Abdo A , Sharaf EA . Mining association patterns of drug-inter- 
actions using post marketing FDAâ€™s spontaneous reporting data. J Biomed Inform 
2016;60:294â€“308 . 

[73] Van Puijenbroek EP , Egberts AC , Heerdink ER , Leufkens HG . Detecting drugâ€“drug 
interactions using a database for spontaneous adverse drug reactions: an example 
with diuretics and non-steroidal anti-inï¬‚ammatory drugs. Eur J Clin Pharmacol 
2000;56(9-10):733â€“8 . 

[74] Thakrar BT , Grundschober SB , Doessegger L . Detecting signals of drugâ€“drug inter- 
actions in a spontaneous reports database. Br J Clin Pharmacol 2007;64(4):489â€“95 . 
[75] Iyer  SV ,  Harpaz  R ,  LePendu  P ,  Bauer-Mehren  A ,  Shah  NH .  Mining clinical 
text for signals of adverse drugâ€“drug interactions. J. Am. Med. Inform. Assoc. 
2014;21(2):353â€“62 . 

[76] Duke JD , et al. Literature based drug interaction prediction with clinical assess- 
ment using electronic medical records: novel myopathy associated drug interac- 
tions. PLoS Comput Biol 2012;8(8):e1002614 . 

[77] LePendu P , Iyer SV , Fairon C , Shah NH . Annotation analysis for testing drug safety 
signals using unstructured clinical notes. J Biomed Semantics 2012;3(Suppl 1):S5 . 
[78] Segura-Bedmar I , MartÃ­nez P , de Pablo-SÃ¡nchez C . Using a shallow linguistic kernel 
for drugâ€“drug interaction extraction. J Biomed Inform 2011;44(5):789â€“804 . 
[79] White RW , Tatonetti NP , Shah NH , Altman RB , Horvitz E . Web-scale phar- 
macovigilance: listening to signals from the crowd. J Am Med Inform Assoc 
2013;20(3):404â€“8 . 

[80] Yang H , Yang CC . Harnessing Social Media for DrugDrug Interactions Detection. 
In: Proceedings of IEEE International Conference on Healthcare Informatics; 2013. 
p. 22â€“9 . 

[81] Yang CC , Yang H , Jiang L . Postmarketing Drug Safety Surveillance using Publicly 
Available Health Consumer Contributed Content in Social Media. ACM Transac- 
tions on Management Information Systems (TMIS) 2014;5(1):2â€“21 . 

[82] Cattral R , Oppacher F , Deugo D . Supervised and Unsupervised Data Mining with an 
Evolutionary Algorithm. Proceedings of the Congress on Evolutionary Computation 
2001:767â€“74 . 

[83] Zheng Y , Peng H , Zhang X , et al. DDI-PULearn: a positive-unlabeled learning 
method for large-scale prediction of drug-drug interactions. BMC Bioinformatics 
2019;20(661) . 

[84] Han J , Pei J , Yin Y , Mao R . Mining frequent patterns without candidate gener- 
ation: A frequent-pattern tree approach. Data Mining and Knowledge Discovery 
2004;8:53â€“87 . 

[85] Vapnik V , Lerner A . Pattern Recognition Using Generalized Portrait Method. Au- 

tomat. Remote Contr. 1963;24:774â€“80 . 

[86] GarcÃ­a-Gonzalo E , FernÃ¡ndez-MuÃ±iz Z , GarcÃ­a Nieto PJ , Bernardo SÃ¡nchez A , 
MenÃ©ndez FernÃ¡ndez M . Hard-Rock Stability Analysis for Span Design in Entryâ€“
Type Excavations with Learning Classiï¬ers. Materials (Basel) 2016;9(7):531 . 
[87] Patle A, Chouhan DS. SVM kernel functions for classiï¬cation. In: International 
Conference on Advances in Technology and Engineering (ICATE); 2013. p. 1â€“9. 
doi: 10.1109/ICAdTE.2013.6524743 . 

[88] Ayyad SM , Saleh AI , Labib LM . Gene expression cancer classiï¬cation using modiï¬ed 

K-Nearest Neighbors technique. Biosystems 2019;176:41â€“51 . 

[89] Yan C, Duan G, Pan Y, Wu FX, Wang J. DDIGIP: predicting drug-drug interactions 
based on Gaussian interaction proï¬le kernels. BMC Bioinformatics 2019;24(Suppl 
15):538 20. doi: 10.1186/s12859-019-3093-x . 

[90] Zhang Q , Guan X , Wang H , Pardalos PM . Maximum shortest path interdiction prob- 
lem by upgrading edges on trees under hamming distance. Optimization Letters 
2021:1â€“20 . 

[91] Wang D , Tan X . Robust distance metric learning via Bayesian inference. IEEE Trans- 

actions on Image Processing 2017;27(3):1542â€“53 . 

[92] Breiman L . Random Forests. Machine Learning 2001;45:5â€“32 . 
[93] Yaman E , Subasi A . Comparison of Bagging and Boosting Ensemble Machine 
Learning Methods for Automated EMG Signal Classiï¬cation. Biomed Res Int 
2019;2019:9152506 . 

[94] Wang MWH , Goodman JM , Allen TEH . Machine Learning in Predictive Toxicol- 
ogy: Recent Applications and Future Directions for Classiï¬cation Models. Chem 
Res Toxicol 2021;34(2):217â€“39 . 

[95] Azar AT , Elshazly HI , Hassanien AE , Elkorany AM . A random forest classiï¬er for 
lymph diseases. Comput Methods Programs Biomed 2014;113(2):465â€“73 . 
[96] Sahoo AJ , Kumar Y . Seminal quality prediction using data mining methods. Technol 

Health Care 2014;22(4):531â€“45 . 

[97] Mittal M , Balas VE , Goyal LM , Kumar R . Big Data Processing Using Spark in Cloud. 

Springer; 2018 . 

[98] Hansen PW , Clemmensen L , Sehested TSG , Fosbol EL , Torp-Pedersen C , Kober L , 
et al. Identifying Drug-Drug Interactions by Data Mining: A Pilot Study of Warfar- 
in-Associated Drug Interactions. Circ. Cardiovasc. Qual. Outcomes. 2019;9:621â€“8 . 
[99] Rosen  CA .  Pattern  classiï¬cation  by  adaptive  machines.  Science 

1967;156(3771):38â€“44 . 

[100] Shtar  G,  Rokach  L,  Shapira  B.  Detecting  drug-drug  interactions  using  ar- 
tiï¬cial  neural  networks  and  classic  graph  similarity  measures.  PLoS  One 
2019;14(8):e0219796. doi: 10.1371/journal.pone.0219796 . 

[101] Huang GB , Chen YQ , Babri HA . Classiï¬cation ability of single hidden layer feed- 

forward neural networks. IEEE Trans Neural Netw 2000;11(3):799â€“801 . 

[102] Ranka S , Mohan CK , Mehrotra K , Menon A . Characterization of a Class of Sigmoid 
Functions with Applications to Neural Networks. Neural Netw 1996;9(5):819â€“35 . 
[103] Mathias AC , Rech PC . Hopï¬eld neural network: the hyperbolic tangent and the 

piecewise-linear activation functions. Neural Netw 2012;34:42â€“5 . 

[104] Wang SH , Phillips P , Sui Y , Liu B , Yang M , Cheng H . Classiï¬cation of Alzheimerâ€™s 
Disease Based on Eight-Layer Convolutional Neural Network with Leaky Rectiï¬ed 
Linear Unit and Max Pooling. J Med Syst 2018;42(5):85 . 

[105] Cao C , Liu F , Tan H , et al. Deep Learning and Its Applications in Biomedicine. 

Genomics Proteomics Bioinformatics 2018;16(1):17â€“32 . 

[106] Zhang Z . NaÃ¯ve Bayes classiï¬cation in R. ANN Transl Med 2016;4(12):241 . 
[107] Huang Y, Li L. Naive Bayes classiï¬cation algorithm based on small sample set. 
In: IEEE International Conference on Cloud Computing and Intelligence Systems; 
2011. p. 34â€“9. doi: 10.1109/CCIS.2011.6045027 . 

[108] Cami A , Manzi S , Arnold A , et al. Pharmacointeraction network models predict 

unknown drug-drug interactions. PLoS ONE 2013;8:e61468 . 

[109] Huang J , Niu C , Green CD , Yang L , Mei H , Han J-DJ . Systematic Prediction 
of Pharmacodynamic Drug-Drug Interactions through Protein-Protein-Interaction 
Network. PLoS Comput Bio 2013;l9(3):e1002998 . 

[110] Cheng F , KovÃ¡cs IA , BarabÃ¡si AL . Network-based prediction of drug combinations. 

Nat Commun 2019;10(1):1806 . 

[111] Cheng F , Zhao Z . Machine learning-based prediction of drugâ€“drug interactions by 
integrating drug phenotypic, therapeutic, chemical, and genomic properties. J Am 
Med Inform Assoc 2014;21:e278â€“86 . 

[112] Vilar S , Harpaz R , Uriarte E , Santana L , Rabadan R , Friedman C . Drug-drug in- 
teraction through molecular structure similarity analysis. J Am Med Inform Assoc 
2012;19(6):1066â€“74 . 

[113] Vilar S , Uriarte E , Santana L , Tatonetti NP , Friedman C . Detection of drugâ€“
drug  interactions  by  modeling  interaction  proï¬le  ï¬ngerprints.  PLOS  ONE 
2013;8(3):e58321 . 

[114] Vilar S , Uriarte E , Santana L , Lorberbaum T , Hripcsak G , Friedman C , Tatonetti N . 
Similarity-based modeling in large-scale prediction of drug-drug interactions. Na- 
ture Protocols 2014;9(9):2147â€“63 . 

[115] Vilar S , Lorberbaum T , Hripcsak G , Tatonetti N . Improving detection of arrhythmia 
drug-drug interactions in pharmacovigilance data through the implementation of 
similarity-based modeling. PLoS ONE 2015;10(6) . 

[116] Sornalakshmi K , et al. A survey on using social media data analytics for pharma- 

covigilance. Res. J. Pharm. Technol. 2017(10):3474â€“8 . 

[117] Gottlieb A , Stein G , Oron Y , Ruppin E , Sharan R . INDI: a computational framework 
for inferring drug interactions and their associated recommendations. Mol Syst Biol 
2012;8:592 . 

[118] Herrero-Zazo M , Lille M , Barlow D . Application of machine learning in knowledge 

discovery for pharmaceutical drug-drug interactions. KDWeb; 2016 . 

[119] Tatonetti NP , Fernald GH , Altman RB . A novel signal detection algorithm for iden- 
tifying hidden drug-drug interactions in adverse event reports. J AM Med Inform 
Assoc 2012;19(1):79â€“85 . 

[120] Vilar S , Friedman C , Hripcsak G . Detection of drug-drug interactions through data 
mining studies using clinical sources, scientiï¬c literature and social media. Brief 
Bioinform 2018;19(5):863â€“77 . 

[121] Keiser MJ , Setola V , Irwin JJ , Laggner C , Abbas AI , et al. Predicting new molecular 

targets for known drugs. Nature 2009;462:175â€“81 . 

[122] Dhami DS, Kunapuli G, Das M, Page D, Natarajan S. Drug-Drug Interaction Discov- 
ery: Kernel Learning from Heterogeneous Similarities. Smart Health (Amst) 2018 
9-10:88-100. doi: 10.1016/j.smhl.2018.07.007 . 

[123] Park K , Kim D , Ha S , Lee D . Predicting pharmacodynamic drug-drug interac- 
tions through signaling propagation interference on protein-protein interaction net- 
works. PloS one 2015;10(10) . 

[124] Berger SI , Iyengar R . Network analyses in systems pharmacology. Bioinformatics 

2009;25(19):2466â€“72 . 

[125] Willett P . Similarity-based approaches to virtual screening. Biochem Soc Trans 

2003;31:603â€“6 . 

[126] Cha S , Tappert C , Yoon S . Enhancing Binary Feature Vector Similarity Measures. 

Journal of Pattern Recognition Research 2006:63â€“77 . 

[127] Jiajing Z , Yongguo L , Chuanbiao W . MTMA: Multi-task multi-attribute learning 
for the prediction of adverse drugâ€“drug interaction. Knowledge-Based Systems 
2020;199 105978 (ISSN 0950-7051) . 

[128] Jackson D , Somers K , Harvey H . Similarity Coeï¬ƒcients: Measures of Co-Occur- 
rence and Association or Simply Measures of Occurrence? The American Naturalist 
1989;133(3):436â€“53 . 

14 

H. Ibrahim, A. Abdo, A.M. El Kerdawy et al. 

Artiï¬cial Intelligence in the Life Sciences 1 (2021) 100005 

[129] Yamanishi Y , Araki M , Gutteridge A , et al. Prediction of drug-target interaction 
networks from the integration of chemical and genomic spaces. Bioinformatics 
2008;24(13):i232â€“40 . 

[130] Bleakley K , Yamanishi Y . Supervised prediction of drug target interactions using 

bipartite local models. Bioinformatics 2009;25(18):2397â€“403 . 

[131] Jacob L , Vert JP . Protein-ligand interaction prediction: an improved chemoge- 

nomics approach. Bioinformatics 2008;24(19):2149â€“56 . 

[132] Van Laarhoven T , Nabuurs SB , Marchiori E . Gaussian interaction proï¬le kernels for 
predicting drug-target interaction. Bioinformatics 2011;27(21):3036â€“43 . 
[133] Gonen M . Predicting drug-target interactions from chemical and genomic kernels 
using Bayesian matrix factorization. Bioinformatics 2012;28(18):2304â€“10 . 
[134] Gattepaille L . Using the WHO database of spontaneous reports to build joint vec- 
tor representations of drugs and adverse drug reactions, a promising avenue for 
pharmacovigilance. In: IEEE International Conference on Healthcare Informatics 
(ICHI); 2019. p. 1â€“6 . 

[135] Song D , Chen Y , Min Q , Sun Q , Ye K , Zhou C , et al. Similarity-based machine 
learning support vector machine predictor of drug-drug interactions with improved 
accuracies. J Clin Pharm Ther 2019;18(2):268â€“75 44 . 

[136] Mahadevan AA, Vishnuvajjala A, Dosi N, Rao S. A Predictive Model for Drug-Drug 
Interaction Using a Similarity Measure. In: 2019 IEEE Conference on Computa- 
tional Intelligence in Bioinformatics and Computational Biology (CIBCB); 2019. 
p. 1â€“8. doi: 10.1109/CIBCB.2019.8791458 . 

[137] Song  D,  Chen  Y,  Min  Q,  Sun  Q,  Ye  K,  Zhou  C,  Yuan  S,  Sun  Z,  Liao  J. 
Similarity-based machine learning support vector machine predictor of drug-drug 
interactions with improved accuracies. J Clin Pharm Ther 2019;44(2):268â€“75. 
doi: 10.1111/jcpt.12786 . 

[138] Wu H-Y , Chiang C-W , Li L . Text mining for drug-drug interaction. Methods Mol 

Biol 2014;1159:47â€“75 . 

[139] Dere S, Ayvaz S. Prediction of Drug-Drug Interactions by Using Proï¬le Fin- 
gerprint Vectors and Protein Similarities. Healthc Inform Res 2020;26(1):42â€“9. 
doi: 10.4258/hir.2020.26.1.42 . 

[140] Liu N, Chen CB, Kumara S. Semi-Supervised Learning Algorithm for Identify- 
ing High-Priority Drug-Drug Interactions Through Adverse Event Reports. IEEE J 
Biomed Health Inform 2020;24(1):57â€“68. doi: 10.1109/JBHI.2019.2932740 . 
[141] Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database 

for 2018. Nucleic Acids Res 2017. doi: 10.1093/nar/gkx1037 . 

[142] Ayvaz S , Horn J , Hassanzadeh O , et al. Toward a complete dataset of drugâ€“
drug interaction information from publicly available sources. J Biomed Inform 
2015;55:206â€“17 . 

[143] Hunter L , Cohen KB . Biomedical language processing: whatâ€™s beyond PubMed? Mol 

Cell 2006;21:589â€“94 . 

[144] Percha B , Garten Y , Altman RB . DISCOVERY AND EXPLANATION OF DRUG-DRUG 
INTERACTIONS VIA TEXT MINING. Pac Symp Biocomput 2012:410â€“21 . 
[145] Bjornsson TD , Callaghan JT , Einolf HJ , Fischer V , Gan L , et al. The conduct of in 
vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and 
Manufacturers of America (PhRMA) perspective. Drug Metabolism and Disposition 
2003;31:815â€“32 . 

[146] De-Boer A . When to publish measures of disproportionality derived from sponta- 

neous reporting databases? Br J Clin Pharmacol 2011;72(6):909â€“11 . 

[147] Vilar  S ,  Uriarte  E ,  Santana  L ,  Tatonetti  NP ,  Friedman  C .  Detection  of 
drug-drug interactions by modeling interaction proï¬le ï¬ngerprints. PLoS One 
2013;8(3):e58321 . 

[148] Vilar S , Harpaz R , Chase HS , et al. Facilitating adverse drug event detection phar- 
macovigilance databases using molecular structure similarity: application rhab- 
domyolysis. J Am Med Inform Assoc 2011;18(Suppl 1):i73â€“80 . 

[149] Wishart DS , et al. DrugBank: a knowledgebase for drugs, drug actions and drug 

targets. Nucleic Acids Res 2008;36(Database issue):D901â€“6 . 

[150] Bjornsson TD , Callaghan JT , Einolf HJ , Fischer V , Gan L , et al. The conduct of in 
vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and 
Manufacturers of America (PhRMA) perspective. Drug Metabolism and Disposition 
2003;31(7):815â€“32 . 

[151] Matthews EJ , et al. Identiï¬cation of structure-activity relationships for adverse ef- 
fects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early de- 
tection of drug-induced hepatobiliary and urinary tract toxicities. Regul Toxicol 
Pharmacol 2009;54:23â€“42 . 

[152] Frid AA , Matthews EJ . Prediction of drug-related cardiac adverse eï¬€ects in human- 
sâ€“B: use of QSAR programs for early detection of drug-induced cardiac toxicities. 
Regul Toxicol Pharmacol 2010;56:276â€“89 . 

[153] Greene N , Judsona PN , Langowskia JJ , Marchanta CA . Knowledge-based expert 
systems for toxicity and metabolism prediction: DEREK, StAR, and METEOR. SAR 
& QSAR. Environ. Res. 1999;10(2-3):299â€“313 . 

[154] Song  D,  Chen  Y,  Min  Q,  Sun  Q,  Ye  K,  Zhou  C,  Yuan  S,  Sun  Z,  Liao  J. 
Similarity-based machine learning support vector machine predictor of drug-drug 
interactions with improved accuracies. J Clin Pharm Ther 2019;44(2):268â€“75. 
doi: 10.1111/jcpt.12786 . 

[155] Lu Z . Information technology in pharmacovigilance: Beneï¬ts, challenges, and fu- 
ture directions from industry perspectives. Drug Healthc Patient Saf 2009;1:35â€“45 . 

15 

